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Abstract    
 
Treatment of pancreatic cancer involves combinations of therapeutics including use of the 
chemotherapy agent gemcitabine. This thesis aimed to identify gemcitabine resistance mechanisms 
in pancreatic cancer and so enable discovery of biomarkers to tailor chemotherapy. Clonally and 
adaptively resistant pancreatic cancer cell lines were developed, producing five clonally resistant 
cell lines (Suit-2R, Suit-2R2, Suit-2R3, Suit-2R4, Panc-R), and an adapted line (Suit-2G+). Removing 
the drug from Suit-2G+ restored sensitivity, giving Suit-2G- cells.  Gemcitabine can cause double 
strand DNA (dsDNA) breaks by incorporation into DNA and as a result of replicative stress induced 
by deoxynucleotide (dNTP) starvation. dsDNA breaks were assessed with neutral comet assays, 
using gemcitabine or gamma radiation. All resistant cell lines had less damage than their parent cell 
line did at low doses of gemcitabine; Suit-2R2 had increased dsDNA breaks at high (250nM) levels. 
Suit-2G cells were less sensitive to radiation and for Suit2-R2, R3 and R4 it was greater, with the 
greatest increase in R4. Gemcitabine starves cells of dNTPs by inhibiting ribonucleotide reductase 
(RR). Suit-2R and Suit-2R4 had low levels of the RR subunit RRM1, Suit-2R2, Suit-2R3, Panc-R and 
Suit2G+ had higher levels. Replicative stress caused by gemcitabine incorporation, due to dNTP 
starvation or dsDNA breaks, can be prevented by checkpoint arrest. Expression of the checkpoint 
protein p21 was reduced in all resistant Suit-2 lines but increased in Panc-R. Chk1 was reduced in 
Suit-2R and increased in Suit-2R3, R4 and Panc-R. Suggesting that in Suit-2R there was a reduction 
in need/ability to activate checkpoints, while in Suit-2R3 and R4 checkpoint arrest had become 
predominantly Chk1 dependent (more G2/M focused). Replicative stress can also be reduced by 
decreasing Cyclin D1 or by relative increase in the D1b isoform (slowing S-phase entry). Panc-1 is 
homozygous for G870A of cyclin D1 and so has more D1b, whereas Suit-2 is heterozygous. Suit-
2G+/G- had increased D1a. Suit-2R and Suit-2R2 have reduced D1 with a higher proportion of D1b. 
Suit-2R3 and Suit-2R4 have higher D1a. Cell cycle analysis tied together these results and suggested 
distinct resistance mechanisms. A: Suit-2G+ has a normal cell cycle; increased nucleotide pools 
overcome replicative stress. B: Suit-2R, Suit-2R2 pause at G1/S, preventing S-phase entry. Starved 
nucleotide pools in Suit-2R, and low Cyclin D1 and Chk1 inducing an arrest in Suit-2R2. C: Suit-
2R3/R4 have many viable cells in G2, driving through S phase accepting replicative stress. D: Panc-R 
has a measured and controlled cell cycle through high RRM1.  
The different ways of achieving resistance identified in cell lines may have equivalents in patients, 
identification of the dominant mechanism can be exploited as a therapeutic biomarker.
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RB   Retinoblastoma protein 
RPMI  Roswell Park Memorial Institute 
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Aim   
 
To identify innate mechanisms of resistance to gemcitabine through exposure in pancreatic cancer 




a) To generate gemcitabine resistant pancreatic cancer cell lines 
b) To assess the growth rates of control and resistant pancreatic cancer cell lines 
c) To compare the expression of gemcitabine molecular targets in sensitive control and resistant 
pancreatic cancer cell lines 
d) Induce transient resistance to gemcitabine by exposure to gemcitabine and verify loss of 
resistance through removal of drug 
e) Assess the cytotoxic effects of gemcitabine by analysis of double stranded DNA damage in all 
cell lines  
f) Assess the cytostatic effects of gemcitabine through mRNA transcript and protein levels 
analysis of the ribonucleotide reductase complex sub-units in all cell lines 
g) Explore the effect of knockdown and transfection of RRM1 transcript on growth and 
resistance to gemcitabine in all cell lines  
h) Assess the effect of gemcitabine resistance on the cell cycle checkpoint control markers p21, 
CyclinD1 and Chk1 in all cell lines 
i) Analyse the combined effects of gemcitabine on the cell cycle phases of all control and 
resistant cell lines, relating them to DNA damage, nucleotide resources and cell cycle 
regulation  




Pancreatic cancer is one of the few malignant diseases that has progressed little with respect to 
overall survival. Even though surgery is the mainstay of curative treatment, it is offered to relatively 
few patients (1, 2). Therefore, the role of chemotherapy is of significant importance, not necessarily 
through a curative strategy but in order to prolong life.  Gemcitabine has formed a critical part of 
adjuvant and palliative chemotherapy for many years, and remains so through multiple randomised 
clinical trials reviewing combinations and alternative agents (3-6). With a disease that affords few 
curative surgeries, resistance to chemotherapy agents brings exceptionally poor survival. It is 
important that patients have at least one option of effective treatment, and that premise forms the 
rationale of this thesis.  
 
1.1 Incidence and prevalence of pancreatic cancer 
 
The awareness of pancreatic cancer is slowly increasing worldwide, with the number of annual deaths 
from the disease expected to exceed that of breast cancer in Europe, over the next few years (7). 
Across the world the incidence of pancreatic cancer was 458,918 in 2018 with 432,242 mortalities, 
giving an age standardised incidence rate of 5.5 per 100,000 and a mortality rate of 4.8 per 100,000 
(8). It predominately occurs across Asia and Europe with incidence proportions of 46.7% and 28.9% 
respectively. There is a slight male preponderance with incidence rates per 100,000 of 5.5 in men 
and 4.0 in women (8). The five-year survival rates range between 3% and 9% across the world (2, 9, 
10).    
 
1.2 Pathology and Staging 
 
The majority of pancreas carcinoma is ductal adenocarcinoma which accounts for over 85% of 
tumours. For lesions that obstruct the distal bile duct, clinical presentation and investigations are the 
same and often lead to identical surgical management. The differential includes distal 
cholangiocarcinoma, duodenal carcinoma, and peri-ampullary malignancy, which may be intestinal 
or pancreatic type. The size of the tumour and extent of local invasion and distant metastatic spread 
are of paramount importance in determining management strategies, especially with the advent of 
neoadjuvant clinical trials. The staging process of pancreatic cancer is through the TNM classification 
of malignant tumours maintained by the Union of International Cancer Control (11).  
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1.3 Clinical diagnosis 
 
The retroperitoneal location of the pancreas reduces the effect a mass has on the gastrointestinal 
tract and lesions become quite sizeable before they cause any symptoms. If they occur at the head 
of the pancreas, the first noticeable symptom may be jaundice as the distal bile duct becomes 
obstructed. This partly explains why only 10% of patients are able to undergo curative surgery as 
other insidious vague symptoms delay referral and diagnosis (12). Patients complain of non-specific 
symptoms of weight loss, change in appetite, early satiety and vague back pain. Specific 
complications of the disease include obstructive jaundice, malabsorption and late onset diabetes (1). 
The relative lack of specific symptoms and physical signs delay prompt investigation. 
 
1.4 Investigations and pathological diagnosis 
 
There are no serum markers specific to pancreatic cancer but carbohydrate antigen nineteen nine 
(Ca 19-9) is used for many pancreas related conditions. The use of Ca 19-9 as a diagnostic marker has 
become standard across the world with a specificity and sensitivity of 80% and 75-80% respectively 
(13, 14). It is a cell surface antigen glycoprotein expressed on pancreatic cancer cells but is also raised 
in other conditions such as acute and chronic pancreatitis, obstructive jaundice, cholangitis, liver 
cirrhosis and bile duct malignancy (15). There is some evidence it can be used as a prognostic marker 
and it is routinely used for post-operative follow-up (1, 16-18). Imaging is often in the form of cross-
sectional imaging and multi-detector computed tomography (MD-CT) has a sensitivity of 76-100%, a 
specificity of 72% and a positive predictive value of 89%, it is recommended by many guidelines for 
diagnosis and staging (19-22). Positron emission tomography (PET) utilises the radiotracer 18F-fluoro-
2-deoxy-D-glucose (FDG) which builds up in cells with high metabolism, particularly if (as with cancer 
cells) they are not metabolising glucose through the Krebs cycle, and is used for detecting extra-
pancreatic disease. Its role in refining staging has led to it being used in conjunction with MD-CT as 
part of national clinical guidance (19, 20, 23). Endoscopic ultrasound and fine needle aspiration are 
being more utilised to produce high resolution images, especially with lesions smaller than 3cm (19, 
20, 24). It has the ability to obtain cells for cytology and even fragments of tissue for histology and 
may have a role in detecting biomarkers for tailoring chemotherapy regimens. 
 
1.5 Surgical management  
 
Though there are promising studies trialling neoadjuvant chemotherapy for pancreatic cancer, 
surgical resection is the mainstay of curative management. Even so only 10% of patients had surgery 
in 2013-2014 within the United Kingdom and the median survival of patients is 11-23 months and 10-
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27% are alive at five years (1, 25). The key decision regarding surgery lies with the precise location of 
the tumour and its borders with surrounding vascular structures. The definitions of borderline 
resectability (BR) have been established by an international consensus in 2016, in order to 
standardise reporting and MDT decision making (26). They defined BR with respect to anatomical, 
biological and conditional factors and extended features of the disease to incorporate additional 
factors that make surgery high risk. The concerning radiological features are that of stenosis, 
deformity, narrowing or occlusion of major vessels and concerning biological features include 
presence of metastatic disease and lymph node disease. The final conditional features are those 
regarding the patient and their fitness and suitability for operative intervention (26). Whether the 
patient has surgery or not, there is certainly a role for palliative and adjuvant chemotherapy and, 
with the completion of recent trials, neoadjuvant too.  
 
1.6 Adjuvant and Neoadjuvant therapy  
 
Over the past twenty years multicentre randomised control trials have been the mainstay of 
pancreatic cancer research and evolving management regimes. The European Study Group for 
Pancreatic Cancer (ESPAC) have produced multiple randomised trials beginning with ESPAC-1 
published in 2004 that found adjuvant chemotherapy led to a five-year survival of 21% compared to 
10% in the chemoradiotherapy group and 8% in the observation group (6). The ESPAC-3 trial 
demonstrated adjuvant gemcitabine was similar in survival to 5-fluorouracil/folinic acid but had a 
lower toxicity profile, becoming the standard of care for a long period of time (4). ESPAC-4 
randomised patients into two treatment paradigms: gemcitabine vs gemcitabine and capecitabine 
(GEMCAP) and found a median survival advantage of 28 months over 25.5 months with the 
combination group (5). This study was particularly important as it started a trend of combination 
chemotherapy for pancreatic cancer. A Canadian and French group performed a multicentre 
randomised control trial reviewing gemcitabine compared with a modified dose combination of 5-
fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) (27). They discovered a median 
survival of 54.4 months in the FOLFIRINOX group compared to 35 months with gemcitabine. There 
was a greater proportion of serious adverse events, 75.9% with FOLFIRINOX compared to 52.9% with 
gemcitabine (27). At present the NICE (National Institute of Clinical Excellence) guidelines do not 
recommend FOLFIRINOX as adjuvant treatment but GEMCAP, and for those not well enough to 
tolerate combined six cycles of treatment, gemcitabine monotherapy (21).  
Gemcitabine has not been incorporated as a single agent for neoadjuvant treatment in any 
randomised controlled trials, but has been retrospectively analysed (28-30). Many recent trials have 
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found utility with FOLFIRINOX in borderline and locally advanced pancreatic cancer patients and a 
few meta-analyses have demonstrated this (31-33). The general outcomes are that there are up to 
60% increases in resectability in tumours that were high risk and there is a marked improvement in 
downstaging and complete margin free resections. This has led to the conclusions that neoadjuvant 
treatment with FOLFIRINOX does lead to increased survival and improved histological outcomes in 
patients with locally advanced or unresectable pancreatic cancer (31-33). There has yet to be a phase 
III trial but ESPAC-5F was a phase II randomised multicentre trial with four arms: primary surgery, 
neoadjuvant FOLFIRINOX, neoadjuvant GEMCAP and neoadjuvant chemoradiotherapy. Of 88 
patients, all neoadjuvant treatments resulted in increased one year survival with 77% alive at one 
year compared to 40% in the straight to surgery group (3). Though we are waiting long term 
outcomes, it would appear that the future of neoadjuvant chemotherapy is almost here. The 
combinatorial drug strategy has been pursued because of the poor outcomes with adjuvant 
monotherapy and the degree of resistance that exists. 
 
Though we can accurately stage and diagnose patients, tumour heterogeneity prevents predictability 
of chemotherapeutic treatment. We are unable to delineate which patient that receives GEMCAP or 
gemcitabine will respond giving a survival advantage, and this applies to the neoadjuvant FOLFIRINOX 
trials in predicting tumour downstaging. Though a multi-drug regimen is unlikely to have a unified 
resistance to all the agents, there will be a degree of cross-resistance mechanisms. Even that is 
beyond the current evidence base as biomarkers to predict gemcitabine resistance have not yet been 
established. 
1.7 Palliative chemotherapy  
 
In the setting of metastatic pancreatic cancer, gemcitabine has historically played a major role and 
now has been trialled with and against more promising regimens such as FOLFIRINOX and nab-
paclitaxel. The PRODIGE4/ACCORD 11 enrolled 342 patients and found median overall survival was 
significantly improved with FOLFIRINOX, 11.1 months vs 6.8 months with gemcitabine but the former 
group had poorer outcomes if they were confined to bed during a significant part of the day (34). 
Long term follow-up of the phase III MPACT trial of 861 patients found a significant increase in 
survival when gemcitabine was combined with nab-paclitaxel compared to gemcitabine alone, 8.7 vs 
6.6 months (35). NICE guidance recommends FOLFIRINOX in patients that have a good performance 
status and gemcitabine in combination with nab-paclitaxel for this who do not. If patients suffer 
adverse effects from combinatorial therapy then gemcitabine alone is then advocated (21).  
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1.8 Principles of chemotherapy resistance 
 
The general principles of resistance are thought to be either primary or secondary, where patients 
either fail to respond to therapy completely or gradually the response diminishes over time. The 
primary resistance mechanisms are thought to be associated with the tumour microenvironment, 
cell signalling or aberrant apoptotic pathways. Secondary resistance involves clonal selection, 
initiation of cell cycle arrest, downstream marker activation or senescence and genetic mutation (36). 
In either group it is imperative to identify the potential biomarkers that either predict primary or 
secondary resistance. Then it would be possible to not only select which treatment modality is best 
but also the organisation of treatment. Though specifically not predictive biomarkers, tailored 
treatment has been achieved in breast cancer with the use of trastuzumab in HER2 positive disease 
and in malignant melanoma with the use of BRAF inhibitors in mutant BRAF patients (37). Developing 
on from this, it is then possible to consider targeted therapies that may overcome the acquired 
resistance and provide a second hit to the tumour. Malignant melanoma is an example where the 
use of MEK inhibition may overcome BRAF inhibitor resistance, but even this strategy has not 
translated to other cancers. Even the timing and dosing of a chemotherapeutic drug may affect its 
resistance and some cancers that are resistance then become sensitive in the absence of the drug. 
The principles of intermittent dosing and continuous dose of medications may have a role in 
overcoming this. Having a second agent that can induce sensitivity to a cell line, such as inducing 
senescence prior to using a senolytic drug is an effective tailored approach (37). This would allow 
multi-targeted specific chemotherapy regimens as opposed to an effective but heavily toxic 
combination of medications. That would be the optimal aim and given that there are only two NICE 
recommended treatment regimens for pancreatic cancer, and that gemcitabine is included in both 
of those strategies, a study of its resistance mechanisms is certainly warranted.  
 
1.9 The metabolism and mechanism of action of gemcitabine  
 
Gemcitabine (2’,2’-difluoro 2’-deoxycytidine, dFdC) is a deoxycytidine analogue and has a dual 
mechanism of functions, cytostatic and cytotoxic. Practically it is given as an intravenous infusion and 
its uptake into the cell is an active or facilitated process, through the function of nucleoside 
transporters, including human equilibrative nucleoside transporter 1 (hENT1). This provides 
bidirectional passage and the roles of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) are 
essential for the activation and deactivation of dFdC. There is a triple phosphorylation process 
initiated by dCK to produce dFdC monophosphate, which is then converted to di- and triphosphate 
through the actions of further pyrimidine kinases. The deamination process to inactivate the 
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phosphorylated and non-phosphorylated dFdC is carried out by deoxycytidylate transaminase (DCTD) 
and CDA respectively. This eventually forms difluorodeoxyuridine and CDA facilitates transportation 
of the degraded gemcitabine out of the cell.  
 
The diphosphorylated form (dFdCDP) is responsible for the cytostatic effects of gemcitabine as it 
binds to ribonucleotide reductase subunit 1 (RRM1) which forms part of the ribonucleotide reductase 
complex (RR) to supply deoxyribonucleotide triphosphates (dNTP) for DNA replication. The binding 
of RRM1 prevents it combining as a tetramer with RRM2, and halts the addition of a phosphate to 
deoxyribonucleotide diphosphate (dNDP). There is an additional component to the RR complex, 
p53R2 which is expressed through DNA damage and oxidative stress through a p53 initiated pathway. 
p53R2 is able to substitute RRM2 in order to maintain or increase the function of RR. The 
triphosphorylated form (dFdCTP) forms the cytotoxic response of gemcitabine and causes direct DNA 
damage. As it competes with dNTPs for incorporation with DNA, there is DNA polymerase 
dislodgement leading to “masked chain termination”. There is also aberrant topoisomerase-I 
cleavage which in combination with direct incorporation induced double strand breaks. The dual 
action of gemcitabine causes replicative stress and induces cell cycle arrest in G1 or S phase, leading 
to abnormal replication or the initiation of pro-apoptotic pathways. The effects of gemcitabine are 
shown in Figure 1.  









1.10 Gemcitabine resistance mechanisms 
 
 
1.9.1  Nucleoside transporters   
 
Gemcitabine is transported into the cell by hENT1 (amongst other transporters), in an inactive form. 
It stands to reason that alterations in the expression of hENT1 will affect a change in the effectivity 
of dFdC. There is some cell line evidence of hENT1 knockdown reducing gemcitabine uptake, by way 
of experimenting on low hENT1 expression through cells with natively reduced levels, through 
combination chemotherapeutic agents and knockdown studies. It was found that low hENT1 leads to 
a reduction in the effectivity of gemcitabine (36, 38, 39). Immunohistochemistry experiments on 
tumour microarrays and publications from our group have demonstrated that low hENT1 protein 
levels is predictive of a poor response to gemcitabine. There was a difference of 9.1 months in overall 
Figure 1  Diagram depicting the phosphorylation of gemcitabine into its cytostatic 
diphosphorylated form (dFdCDP) and its cytotoxic triphosphorylated form (dFdCTP). (hENT1: Human 
equilibrative nucleotide transporter 1, dFdU: Uracil inactive metabolite, -MD, -DP, -TP: mono-, di-, 
triphosphate CDA: Cytidine deaminase, dCK: deoxycitidine kinase, 5-NT: 5’ Nucleotidase, DCTD: 
Deoxycytidylate deaminase, dCTP: deoxynucleoside triphosphates, NMPK/NDPK: nucleoside mono-
/diphosphate kinase, dNDP: nucleoside triphosphate, dNTP: nucleoside triphosphate)  
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survival in patients that received adjuvant gemcitabine with a non-significant advantage for low 
hENT1 in patients treated with 5-FU (40, 41). A meta-analysis of seven pancreatic cancer studies 
found hENT1 expression was significantly associated with prolonged disease-free survival and overall 
survival in patients receiving gemcitabine (42).  
 
1.9.2. Activation of gemcitabine 
 
The phosphorylation of dFdC is an essential step towards the active form and there have been many 
studies investigating the role of dCK in the resistance of gemcitabine. From an in vitro perspective 
there have been multiple developed gemcitabine resistant cancer cell lines that have shown missense 
and deletion mutations in dCK and reduction in its protein levels (43, 44). There has also been a 
described effect of NRF-2 driven antioxidant transcription from decreased dCK, that contributes to 
gemcitabine resistance (45). From a patient perspective there have been some associations with 
overall survival. RT-PCR was performed in pancreatic cancer patients receiving adjuvant gemcitabine 
and stratified into low and high dCK, and a 9.2 month overall survival difference was noted in patients 
with high dCK mRNA transcript (46). This was not seen in experiments on tumour tissue. 
Immunohistochemistry experiments on intestinal type cancers demonstrated a better prognosis with 
high dCK protein levels, but not pancreatobiliary (47). Though there is a clear hypothetical advantage 
to increased dCK expression, increasing sensitivity to gemcitabine, this has not been demonstrated 
at a clinical level.  
 
1.9.3 Direct DNA incorporation 
 
As gemcitabine attempts to insert its triphosphate into DNA, polymerases may pause at the 3'-
terminal or 3'-penultimate position after where dFdC is incorporated (36). Exonucleases can excise 
mismatched deoxyribonucleotides but experiments focused on the excision of the gemcitabine 
nucleotide found they are difficult to excise. DNA polymerases can actually extend the 3’-dfdCMP 
resulting in internal incorporation of the cell (48). The excision repair cross-complementation 1 
(ERCC1) gene has been theorised to be important in excising gemcitabine, with higher expression 
leading to resistance in non-small cell lung cancer (49). These studies progressed to clinical tissue 
with mRNA levels assessed in tumour tissue demonstrating that ERCC1 may predict poor survival in 
patients treated with gemcitabine but ultimately a phase II trial in NSCLC was halted early due to a 
futility analysis (39, 50). Topoisomerase I (Top1) functions by cleaving DNA and separating strands 
for all functions, transcription, translation, condensation and recombination. It has been discovered 
that reversion of Top1 cleavage complexes is slowed, leading to an accumulation of double strand 
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breaks (51). The only cancer that has shown reduced Top1 is acute myeloid leukaemia where 
resistance to gemcitabine was demonstrated.  Gemcitabine may also induce reactive oxygen species 
through the activation of NF-kB which complements its other cytotoxic mechanisms. The nuclear 
translocation of Nrf-2 initiates transcription of cytoprotective anti-oxidants, and siRNA knockdown 
studies have demonstrated increased sensitivity to gemcitabine (52, 53).   
 
1.9.4 Inhibiting ribonucleotide reductase  
 
Gemcitabine not only incorporates itself into DNA, causing strand breaks but also competitively 
inhibits by combining with the RRM1 subunit, reducing the nucleotide pools. Many studies have 
reviewed the effect of the RR subunits and resistance to gemcitabine. Inhibition of RRM1 through 
binding of dFdCDP reduces the pool of dNTPs. At first this will increase the relative concentration of 
dFdCTP against dFdCTP, therefore increasing the incorporation of dFdCTP into DNA. There will be an 
increased cytotoxic effect and increasing the levels of RRM1 will restore the levels of dNTPs, reducing 
the relative incorporation of dFdCTP. Reduction in dNTPs will eventually lead to an inability to 
replicate DNA and thus replicative stress. Increasing RRM1 reduces this effect, however dNTP levels 
restoration continues DNA replication, but also allows incorporation of dFdCTP leading to DNA breaks 
in dividing cells (43, 54-58). RRM1 studies in the form of clinical research trials is discussed later in 
the thesis.  
 
Our group have investigated which transcripts associated with gemcitabine resistance using Illumina 
Human RNA v3Bead and 810 Protein Antibody microarrays and developed resistant Suit-2 cell lines. 
It was discovered that the RRM2 subunit was differentially expressed in the resistant cell line and 
that its reduction at a transcript and protein level garnered resistance. Other studies looking at RRM2 
have also found that increases in RRM1 and RRM2 in developed gemcitabine resistant Panc-1 cell 
lines reduced sensitivity (59). p53R2 is inducible by DNA damage through a p53 mediated pathway 
and has never been shown to be significant in pancreatic cancer. There has been a suggest that it can 
be used as a prognostic marker in nasopharyngeal cancer and increased mRNA expression may afford 
resistance to gemcitabine in cholangiocarcinoma patients (60, 61). Given its role as a substitute to 
RRM2 and its regulation by p53, it is reasonable to assume that p53 mutations will have an impact 
on gemcitabine resistance via regulation of ribonucleotide reductase. This is complicated by the fact 
that different p53 mutations will have varying impact by regulation of p53R2 and some mutations 
will reduce expression of apoptosis related genes but not p53R2. Alternate mutations will inhibit 
p53R2 regulation but have no impact on other cell cycle regulators and apoptotic proteins (62, 63). 
Kulbir Man: Introduction 
 19 
1.10 Cell cycle regulation  
 
There are many signalling pathways and checkpoint regulators that ensure propagation of successful 
DNA replication and arrest in order to repair or enter pro-apoptotic pathways. Gemcitabine induces 
stress replication and in order to overcome this, there must be either repair pathways initiated or 
apoptosis induced, with either strategy there will be alterations to the cell cycle checkpoints. The 
following markers have been found to have an important role in pancreatic tumourigenesis or have 
been previously investigated by our unit. They are summarised in figure 2.  
 
 
Figure 2  A diagram depicting the cell cycle and the checkpoints with pertinent markers 
discussed within this thesis. (CDK: Cyclin dependent kinases, PAK: p21 associated kinases, CDC: 
complement dependent cytotoxicity, RB: Retinoblastoma protein, E2F: E2 transcription factor, dNDP: 
nucleoside triphosphate, dNTP: nucleoside triphosphate, ATM/ATR: Ataxia-telangiectasia-mutated 
and ataxia telangiectasia Rad3-related (ATR) proteins) 
  
1.10.1  p21   
 
p21 is induced by p53 and enacts a number of effector mechanisms through the inhibition of cyclin 
dependent kinases and proliferating cell nuclear antigen, all required for S-phase progression. 
Thereby this enables cell cycle arrest, senescence, DNA repair and potentially apoptosis. Not only 
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does it have a direct inhibition of the cell cycle kinases it also mediates p53-dependent gene 
repression of cell cycle regulators including Chk1, CyclinB1, CDC2 and CDC25. p21 has a complex 
relationship with apoptosis and can actually act as an inhibitor in order to maintain arrest. It is 
theorised that post translational modifications such as phosphorylation and caspase cleavage can 
differentiate apoptotic and arresting pathways (64). There are p21-activated kinases (PAK) that have 
been implicated in oncogenic signalling pathways that involved in pancreatic cancer. PAK4 has been 
shown to be increased at an mRNA and protein level in multiple pancreatic cancer cell lines and a 
degree of co-amplification with PAK1 and CyclinD1 (65). Further experiments using gemcitabine 
resistant cell lines were found to express higher protein levels of PAK4 and less hENT1. If PAK4 was 
knocked down then sensitivity was restored (66). It has been theorised that PAK1 mediates 
gemcitabine resistance by suppressing DNA damage through the NF-kB pathway. It was also 
discovered that PAK1 was elevated and RRM1 increased in patients with pancreatic cancer (67, 68). 
There are numerous interactions with p21 and the functions of gemcitabine and its role in 
oncogenesis and chemoresistance requires further investigation.   
 
1.10.2  Cyclin D1 
 
The Cyclin D family regulates cyclin dependent kinases (CDK4 and CDK6 predominately) that are 
essential for progression through the G1/S checkpoint. In G1 it rapidly accumulates in the nucleus 
and then degrades once the cell enters S phase (69). Its role in pancreatic oncogenesis has been 
reported in many studies and that increased expression of Cyclin D1 leads to DNA replication and cell 
proliferation in Panc-1 and MiaPaCa pancreatic cell lines. The role of Cyclin D1 and miRNA-720 was 
also established in that the micro-RNA suppresses tumour growth by downregulating Cyclin D1 (70, 
71). This was confirmed by the transfection of Cyclin D1 plasmids in Panc-1 cells where the effect of 
miRNA-720 was abrogated. The DNA encoding Cyclin D1 was found to have a polymorphism at 
position 870, codon 242, exon 4, where a splice variant occurs (Figure 3).  
Figure 3   Cyclin D1a codes exons 1-5 and a 3’ untranslated region. Cyclin D1b encodes exons 1-
4 and intron 4 with a 3’ untranslated region. The expression levels of cyclin D1a/b are influenced by 
the existence of a G/A polymorphism at nucleotide 870, the final nucleotide of exon 4 (72) 
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A and G alleles provide both transcripts but the adenosine produces the aberrant transcript more 
frequently. The G870A polymorphism has been theorised to be associated with a risk of breast, 
colorectal and pancreatic cancer (72-74). The two variants produced are Cyclin D1a and D1b with the 
latter expressing the lighter protein. There is clearly an oncogenic role for Cyclin D1 in pancreatic 
cancer but its effect on gemcitabine resistance and biomarker potential has yet to be established. 
 
1.10.3  Checkpoint Kinase 1 (Chk1) 
 
Chk1 is another cell cycle regulator the facilitates cell cycle arrest in order to facilitate DNA repair. It 
functions at the G2/M checkpoint but is likely to be utilised throughout the cell cycle. It forms part of 
the DNA damage response (DDR), activated by Ataxia-telangiectasia-mutated (ATM) and ataxia 
telangiectasia and Rad3-related (ATR) proteins, with the former mainly in response to double 
stranded damage (75). Increased expression of Chk1 and Chk2 induce cell cycle arrest and DNA repair 
and clearly play a prominent role in the defence against cancer development. Chk1 has been the 
focus of many studies, especially in pancreatic cancer and has been linked to RRM1 and gemcitabine 
effectiveness. Chk1 inhibition has been a focus of clinical drug development but their role as a 
chemosensitizer has yet to be established. Treatment of five different pancreatic cancer lines with a 
Chk1 inhibitor prior to gemcitabine treatment, was shown to enhance DNA damage and cause a 
downregulation in the RR apparatus. This synergistic effect caused growth inhibition and apoptosis 
(76). Further work in pancreatic cancer cells demonstrated that there was not only a G2-M duration 
extension but the replicative stress was a key finding, with a high accumulation of S-phase cells with 
persistent genomic damage (77). Further work has been performed on drug combinations in vitro to 
affect the DDR pathway. The role of Chk1 is essential to DNA repair and cell cycle regulation and it 
has a role in gemcitabine resistance (77, 78).  
 
Gemcitabine resistance is multifactorial and likely to have diverse strategies. The aim of this thesis 
is to develop gemcitabine resistant pancreatic cancer cell lines and then investigate those 
mechanisms. In emulating resistance from a true-to-life patient perspective, where pulsed 
treatments of gemcitabine are administered, there will be translatable revelations. This holds true 
for solid tumour masses treated with neoadjuvant/palliative gemcitabine (potentially acquired 
resistance) and for resected specimens and circulating tumour cells treated with adjuvant 
gemcitabine (potentially clonal cells demonstrating resistance). For both paradigms, investigations 
into the cytotoxic effects, cytostatic effects and cell cycle regulatory mechanisms will provide 
holistic overviews to delineating resistance mechanisms to gemcitabine.
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2.  Materials and Methods 
 
General lab equipment  
 
Heraeus Biofuge Primo Centrifuge   (Thermo Fisher Scientific)  
Heraeus Pico Centrifuge    (Thermo Fisher Scientific) 
Vortex Genie 2     (Scientific Industries Inc.) 
TC10™ Automated Cell Counter   (Bio-Rad Laboratories) 
 
2.1  Cell acquisition and passaging  
 
Suit-2 and Panc-1 cell lines were obtained from stocks provided by the Greenhalf group at Liverpool 
University. Suit-2 is an immortalised pancreatic cancer cell line derived from metastatic liver lesions 
and Panc-1 has been immortalised from a native pancreatic adenocarcinoma. Both these cells lines 
have p53 and KRAS missense mutations of p.R273H and p.G12D respectively. Cells were maintained 
in sterile T75 vented flasks using 25ml of Roswell Park Memorial Institute (RPMI) 1640 medium 
enriched with sodium bicarbonate and 50ml foetal bovine serum (FBS) (10%) and 5ml 200mM L-
glutamine (1%) added to every 500ml stock. These flasks were incubated at 37oC, 5% CO2 in a well-
maintained air humidified incubator. Cells were inspected regularly for any evidence of infection and 
confluence assessed. Once they reached 80-90% confluence then a passage sub-culture was 
undertaken. This performed in a secondary cell culture room which contained the incubator using 
laminar flow biological safety cabinets under strict aseptic conditions. All reagent bottled used for 
culturing were allowed to reach room temperature, whereas they are normally stored at 4oC. The UV 
light was always switched on for fifteen minutes prior to opening the front panel of the hood. The 
use of Trigene disinfectant and 70% ethanol was implemented to clean the base and to all apparatus 
and flasks brought into the hood. New sterile T75 flasks and pipettes and a clean pipette controller 
were used for each passage process. Each flask had all conditioned media removed and a rigorous 
cleaning process using 10ml of phosphate buffered saline and then a five-minute treatment of 3ml 
of trypsin dissociation reagent. With a firm tap cells were completely detached and a further 7ml of 
conditioned RPMI was administered to neutralise the trypsin. A further washing process allowed an 
almost complete cell population in a 10ml solution. Depending on the circumstances either a 1:10 or 
a 1:20 split was performed placing either 0.5ml or 1ml of cell suspension into 19.5 or 19ml of media 
in a fresh T75 flask.   
 




2.2  Cell counting and cryopreservation  
 
General Reagents  
 
Freezing media (X2)  Volume of 100ml: 10ml DMSO, 20ml FBS, 70ml RPMI-1640    
Once cells were at 80-90% they underwent multiple experimental processes including 
cryopreservation. After the trypsination process with 7ml of RPMI additive stock added to the falcon 
tube, cells were centrifuged at 1000xg for 1 minute. This developed a cell pellet once the supernatant 
was discarded that was washed using 5ml of PBS. This was then re-centrifuged and then once 
supernatant discarded, a further wash with PBS performed. 10µL of this cell solution was taken and 
placed onto a cell counting slide for use with the TC20™ automated cell counter. The reading given 
was of cell numbers per millilitre of solution and guided the quantity of cells for each experiment and 
those cryopreserved. The PBS cell solution was then centrifuged once more and then the cell pellet 
washed using a freezing media which contained 500µL of stock RPMI with 500µL of freezing media 
(10%). The cell concentration of the media was 1 million cells/ml and divided into 1.5ml cryogenic 
vials and then underwent a gradual freezing process at initially -80oC and then into a polypropylene 
freeze box to be stored in liquid nitrogen. For resurrection a vial was taken from liquid nitrogen and 
allowed to thaw at room temperature with 500µL of room temperature stock RPMI media. Once 
liquefied the solution was transferred to a 15ml falcon tube and centrifuged at the settings above. A 
two stage 5ml PBS wash was performed to remove the DMSO and allow the cells to be placed into 
stock RPMI media in a T25 or T75 flasks and placed into an incubator. The cells were observed 
regularly to ensure adequate growth prior to appropriate sub-culturing. The passage number of cells 
was always recorded on the flask to ensure experiments were performed with low passage number 
cells to prevent genetic variations and drift.  
 
2.3  Generation of gemcitabine resistant cell lines  
 
General Reagents  
 
Gemcitabine    (SelleckChem Llc)  
 
There were two separate methods used for generating resistant cells and the gemcitabine that was 
utilised was purchased from Selleck Chemicals LLC. The stock solution of gemcitabine was diluted in 
water and had a concentration of 50mM and was stored at 4oC.  
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2.3.1  Generation of Suit-2G cells lines 
 
Suit-2 cell lines were cultured routinely and gemcitabine was gradually added to the culture medium. 
The 50nM stock was diluted to lower concentrations and added to the culture medium of the flask. 
Initially began at 5nM and progressively increased until a concentration of 500µM was achieved. Cells 
were regularly observed for signs of growth and overwhelming cell death and sub-culturing was 
performed when cells were 80-90% confluent or contained significant cellular debris. Cell splitting 
was performed at longer intervals compared to parent Suit-2 cells in the initial phase but once 
gemcitabine was at a higher dose, there was faster and more normal passage times. The Suit-2G+ 
cell line was maintained at a concentration of 500µM of gemcitabine whereas a separate cell line 
was developed, Suit-2G- which was sub-cultured without gemcitabine. Approximately ten passages 
were carried out prior to any ongoing experimentation at the first instance.  
 
2.3.2  Generation of Suit-2R and Panc-R cells lines 
 
The Suit-2R and Panc-R cell lines were developed through a clonal isolation technique which involved 
plating into 96-well flat bottom plates. This is demonstrated in figure 4. Each well was filled with 
100µL of stock RPMI culture medium except for A1, which was left empty. Suit-2 and Panc-1 cells 
were taken at a concentration of 2x104 cells per millilitre and 200µL of this solution was placed into 
the A1 well. Then a double dilution series was performed, firstly vertically then horizontally. 100 µL 
was taken from the A1 cell and them placed into B1, mixing it well using a pipette. This process was 
repeated vertically until the H1 well and then the final 100µL discarded. Then each row was further 
diluted across to the 12th column by adding 100µL of culture medium to column 1, mixing well and 
subsequently moving across diluting each well. The 12th column will have 200µL after mixing and so 
100µL was discarded. This dilution process means that the latter wells at the upper aspect of the 
plate and the former wells at the south end of the plate are likely to contain single cells. These are 
the wells that were closely observed as gemcitabine was added to the wells, after 24hrs allowing the 
cells to seed. Initially a concentration of 5nM was added to each well and the plate observed for the 
next two weeks. The wells that clearly contained multiple cell colonies were ignored/discarded 
whereas the ones with 1-2 cell colonies were observed carefully.  
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Figure 4   Single cell dilution method on a 96-well plate demonstrating initial cell inoculation and 
two serial dilutions, with wells highlighted that are likely to contain one to four cell colonies  
 
There were attempts to add a further gemcitabine dose to the well every 4 days but this resulted in 
no cell growth, and the colonies were lost. Once a colony had succeeded in forming then once it had 
reached 80-90% confluence of the well, it was dissociated using 20µL of trypsin for a few minutes 
prior to adding 180µL of stock RPMI culture medium. This 200µL cell solution was then placed onto 
the A1 well of another 96 well plate and the double dilution process was then repeated. The dose of 
gemcitabine added was then doubled to 10nM and then increased initially through increments of 
10nM and then by 25nM, after achieving 50nM until 250nM was reached. There were four cell 
colonies taken from the initial plating of Suit-2 cells and one from the Panc-1 cells that survived the 
step-wise increases of gemcitabine concentrations until the final dose was reached. At each step, the 
well that reached target confluence was the cell colony that was sub-cultured for the next step. Once 
the target dose of gemcitabine was reached then the next sub-culture was performed in a flat bottom 
six well plate without gemcitabine. The next sub-cultures were carried out using a vented T25 flask 
before building to a T75 flask. It was at this point that cryopreservation steps were performed to 
maintain a frozen stock of resistant cell lines.  
 
2.4  Cell viability assay   
 
General Equipment & Assays  
 
Multiskan Microplate Photometer   (Thermo Fisher Scientific) 
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The EZ4U non-radioactive cell proliferation and cytotoxicity assay is based upon the reduction of 
tetrazolium salts into coloured formazan derivatives. This assay utilises a substrate and activator 
reagent which once applied to viable cells, will turn the solution from straw coloured to red. The 
quantification of this colour change is performed using a microtitre plate reader utilising a 450nm 
wavelength and a 620nm reference wavelength.  
 
Cells were plated at a concentration of 1x105 per ml onto a 96 well plate at a volume of 100µL per 
well. They were allowed to seed overnight prior to gemcitabine treatment. The culture medium was 
not removed but gemcitabine added to the solution, to create a half log concentration from 0.5nM 
gemcitabine to 5µM. There was a control lane of cells cultured without added gemcitabine and also 
the outer wells were kept free from cells. Therefore, there were six rows of cells and each 
concentration of gemcitabine had up to six replicates but for more complex experiments and multiple 
cell lines, triplicates were used. The cells were cultured for 48hrs prior to performing viability assays. 
This was based upon preliminary standardisation experiments to assess the optimal cell densities and 
incubation periods to provide optimal cell viability curves. For more complex experiments involving 
knockdown and transfection experiments, time protocol experiments were carried out to ensure that 
the initial treatment parameter was given sufficient time to function prior to cell viability analysis.  
The EZ4U cell proliferation assay was carried out according to the manufacturer’s protocol. Existing 
culture media was removed from each well and replaced with 200μl of fresh media and 20μl of 
reagent (mixture of substrate and activator) at room temperature. The plates were incubated at 
37°C for 4 hours and readings were taken at 620nm and 450nm wavelengths using a microplate 
spectrophotometer with a shaking plate carrier. The results were analysed using Microsoft® Excel 
version 16.16.23 in order to standardise all cell lines to a 0-1 scale, where 0 represents the highest 
drug dosing and 1 is the control cell replicates. These results were then plotted as a log scale vs 
normalised absorbance and a drug dose sigmoidal curve fitted using GraphPad Prism version 8.42. 
This allowed a calculation of the half maximal inhibitory concentrations (IC50) of the cell lines and 
treatment parameters. 
 
2.5 Extraction of RNA    
 
General Equipment & Assays  
 
RNeasy Mini Kit     (Qiagen) 
EZ4U – Cell Proliferation and Cytotoxicity Assay (Biomedica Medizinprodukte GmbH) 
NanoDrop Spectrophotometer   (Thermo Fisher Scientific) 
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When cells reached 80-90% confluence cultured in a T75 flask, they were dissociated as above, 
neutralised by culture medium and then centrifuged at 1000xg for 5 minutes. After discarding the 
supernatant, a PBS wash was performed and then a further centrifugation process carried out. RNA 
preparation was performed according to the RNeasy Mini Kit protocols. Once the supernatant was 
discarded, 300µL of Buffer RLT was added to the cell pellet, and vortexed to ensure no cell clumps 
were visible. This lysate was pipetted into a QIAshredder spin column placed within a 2ml collection 
tube and then centrifuged at 13,300xg for two minutes. 300µL of 70% ethanol was added to the 
homogenized lysate and a maximum of 700µL was transferred into an RNeasy spin column, placed in 
a 2ml collection tube. This tube was centrifuged at 8000xg for 15 seconds and the flow through was 
discarded. 700µL of Buffer RW1 was added to the RNeasy spin column and a further centrifugation 
process was performed at 8000xg for 15 seconds. The flow through was discarded and 500µL of 
Buffer RPE was added to the RNeasy spin column which was once again centrifuged at 8000xg for 15 
seconds to wash the spin column membrane. The flow through was discarded and another Buffer 
RPE step was performed but for 2 minutes to ensure all ethanol has been removed. The RNeasy spin 
column was removed and placed into a new collection tube and centrifuged for a minute as an extra 
step to remove any carry over RPE buffer. The RNeasy spin column was removed and placed into 
another collection tube and 50µL of RNAse free water applied to the spin column and centrifuged at 
8000xg for a minute. This completed the RNA extraction and purification process and purity was 
assessed using a NanoDrop Spectrophotometer. A 1µL sample of extracted RNA was placed onto the 
pedestal and the Windows-based application software set to RNA-40 settings. A clean spectral image 
was ensured and the RNA quantity was documented as ng/µL. The wavelength ratios 260/280 were 
checked and if the readings were divergent from an accepted purity of 2 (+ 0.4) then the RNA was 
not used for further experiments. The samples were stored at -80oC unless immediately used for 
cDNA preparation.  
 
2.6 Preparation of cDNA  
 
General Equipment & Assays  
 
QuantiTect Reverse Transcription Kit   (Qiagen) 
 
This procedure was performed in a DNA free hood/room with specific equipment only used for this 
process and cleansed using nuclease free water (DNA free in this sense meaning that no purified DNA 
was allowed into the space). All reagents and RNA specimens were thawed on ice and each genomic 
DNA elimination procedure was performed using 1µg of template RNA at a calculated volume 
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according to the concentration, then made up to 12µL using RNase-free water and then 2µL of gDNA 
Wipeout Buffer was added. This was incubated at 42oC for 2 minutes. The reverse-transcriptase 
master mix was made up to 6µL using 1µL of Quantiscript Reverse Transcriptase, 4µL of Quantiscript 
RT buffer and 1µL of RT Primer mix. This was then added to the template RNA mixture making a final 
volume of 20µL and incubated for 15 minutes at 42oC. A final incubation procedure was performed 
at 95oC for 3 minutes to inactivate the reverse transcriptase. These samples were stored at -80oC 
prior to being used for real time PCR reactions.  
 
2.7  Quantitative real-time polymerase chain reaction (RT-PCR) protocols   
 
General Equipment & Assays  
 
Light Cycler 480     (Roche Diagnostics) 
SYBR Green I      (Qiagen) 
Primers      (Eurofins Genomics US) 
 
A Roche Light Cycler 480 was used for all RT-PCR reactions utilising SYBR Green I cyanine dye for DNA 
nucleic acid staining. A master mix of each parameter cDNA, developed as above, contained 7μL 
RNase-free PCR grade water, 10μL SYBR Green and 1μL primer (0.5μL forward and 0.5μL reverse), 
creating a 20μL volume per sample per primer. Generally, the cDNA was often diluted in a 1:10 ratio 
and triplicates performed per primer. Specific Light Cycler 480 96-well plates were used for the 
experiments and each experiment had wells with only sterile nuclease free water and a master mix 
without reverse transcriptase (-RT) as controls. All preparations were carried out in a DNA free 
room/hood with equipment utilised only for these experiments. A sealing foil was then firmly applied 
to the plate prior to being placed into the Light Cycler 480. Table 1 depicts the primer sequences used 
for all experiments and the annealing temperatures. Table 2 demonstrates the conditions required 
for a typical sixty cycle reaction, using a 58oC to 72oC amplification range. CyclinD1a and CyclinD1b 
primers were developed using Primer-BLAST from the National Centre for Biotechnology 
Information. Specific primers crossing exons 4-5 and exon 4 to intron 4 for each isoform. GAPDH was 
used as a housekeeping gene for all other parameters to be normalised to. If there was any 
amplification demonstrated in the water or -RT control wells, then the whole experiment was 
abandoned and repeated. Once melt curves were meticulously checked, the number of cycles where 
threshold level was achieved was recorded. Thresholds were automatically determined based on 
inflection point of the curve. These results were then analysed in Microsoft® Excel version 16.16.23 
for MacOS, normalised to GAPDH and the DDCT method implemented. When experiments were 
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repeated the DDCT were analysed between experimental parent controls and resistant lines using a 
Wilcoxon matched-pairs signed rank test using GraphPad Prism version 8 for MacOS.  
 
Gene Forward Sequence (5’-3’) Reverse sequence (5’-3’) 
RRM1 GGAGGAATTGGTGTTGCTGT GCTGCTCTTCCTTTCCTGTG 
RRM2 CCCGCTGTTTCTATGGCTTC CCCAGTCTGCCTTCTTCTTG 
RRM2B (p53R2) GAGGCTCGCTGTTTCTATGG ATCTGCTATCCATCGCAAGG 
CDKN1A (p21) TAGCAGCGGAACAAGGAG AAACGGGAACCAGGACAC 
Chk1 CTTTGGCTTGGCAACAGT CCAGTCAGAATACTCCTG 
CCND1 (Cyclin D1a) CAAGTGTGACCCRGACTGC AAAATGCTCCGGAGAGGAGG 
CCND1 (Cyclin D1b) TGAGGAGCCCCAACAACTTC GACCTCCCAGCCAGTCAGTA 
GAPDH ATGACCACAGTCCATGCCAT TTGAAGTCAGAGGAGACCAC 
 
 
Table 1  A list of the forward and reverse primer sequences utilised for RT-PCR 
 
Phase Cycle Duration (min) Temperature (oC) 
Pre-incubation 1 5:00 95 
Amplification 60 0:10 95 
  0:10 58-60 
  0:10 72 
Melt 1 0:05 95 
  1:00 65 
Cooling 1 0:10 40 
 
Table 2  A generic RT-PCR protocol for the Roche Light Cycler 480. For amplification phase, the 
annealing temperature was 58oC for RRM1 primers, 59oC for Cyclin D1a and D1a with an additional 
fourth step at 84 oC and 60 oC for RRM2, p53R2, p21, Chk1 and the housekeeping gene GAPDH   
 
2.8  Single Nucleotide Polymorphism Genotyping  
 
General Equipment & Assays  
 
DNeasy Mini Kit     (Qiagen) 
Light Cycler 480     (Roche Diagnostics) 
SYBR Green I      (Qiagen) 
TaqMan SNP Genotyping Assay   (Eurofins Genomics US) 
 
DNA extraction was performed  on cells plated for 48 hours, seeded at 1x105 density in 2ml of stock 
RPMI media per well of a 6 well plate. After the allotted time, the media was extracted and two 2ml 
PBS washes performed per well of the plate. A cell scraper was then used to manually dissociate 
the cells from the base of the plate. A QIAGEN DNeasy kit was used and the initial step involved 
adding 400μl of Buffer AP1 and 4μl of RNase A to each well and then placing into a sterile 1.5ml 
collection tube. The samples were vortexed and left to incubate at 65oC for ten minutes. 130μl of 
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Buffer P3 were added and the samples incubated for five minutes on ice. The lysates were then 
centrifuged for five minutes at 20,000xg. Each sample was then pipetted into a QIAshredder spin 
column within a 2ml collection tube and centrifuged for two minutes at 20,000xg. The flow through 
was transferred into a new tube and the volume was increased by 1.5 using Buffer AW1 and mixed. 
650μl of the solution was placed into a DNeasy Mini spin column within a 2ml collection tube. This 
was the centrifuged again at 6000xg and the flow through discarded. The remaining solution from 
the previous step was also then placed into the same spin column and the centrifugation repeated. 
A further wash was performed using 500μl of Buffer AW2 and centrifuged at 6000xg for one 
minute. A final was wash performed using 500μl of Buffer AW2 and centrifuged for two minutes at 
20,000xg. The DNeasy spin column was placed into a fresh 2ml collection tube and 100μl of the 
elution buffer, Buffer AE was added and incubated for five minutes at room temperature prior to a 
final centrifugation process at 6000xg for one minute. The NanoDrop 2000C spectrophotometer 
was used to quantify the DNA extracted, using similar protocols to RNA quantification as described 
above. Genotypes of all cells, including Panc-1 and the gemcitabine- resistant Panc-R, were 
analysed using a Thermofisher TaqMan SNP Genotyping Assay and a dual-colour hydrolysis probe 
(SNP ID: rs9344). This probe detected a single nucleotide change (G/A), labelled with either the 
FAM (G major allele) or VIC (A minor allele) fluorophore. Duplicate or triplicate assays were 
performed for each cell line and all preparations were carried out in a DNA free room/hood with 
equipment utilised only for these experiments. Allele-specific polymerase chain reaction (AS-PCR) 
was carried out using 10μl LC480 SYBR Green, 2μl probe, 100ng DNA and variable DNase-free PCR 
grade H2O to give a 20μl volume per reaction. A sealing foil was firmly applied to the plate prior to 
it being placed into the Light Cycler 480 and probe specific conditions were applied (Table 3).  
Phase Cycle Duration (min) Temperature (oC) 
Pre-incubation 1 10:00 95 
Amplification 45 0:10 92 
  1:30 60 
  0:03 72 
Cooling 1 0:10 40 
 
Table 3  A generic RT-PCR protocol for the Roche Light Cycler 480. For the amplification phase, 
the annealing temperature of the phase was 58oC for RRM1 primers, 59oC for Cyclin D1a and D1a 
with an additional fourth step at 84 oC and 60 oC for RRM2, p53R2, p21, Chk1 and the housekeeping 
gene GAPDH   
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2.9  Extraction of protein   
 
General Equipment & Assays  
 
RIPA Lysis and Extraction Buffer    (Thermo Fisher Scientific) 
Protease and Phosphatase Inhibitor Cocktail  (Thermo Fisher Scientific) 
Pierce™ BCA Protein Assay Kit   (Thermo Fisher Scientific) 
 
When cells reached 80-90% confluence cultured in a T75 flask, they were dissociated as above, 
neutralised by culture medium and then centrifuged at 1000xg for 5 minutes. After discarding the 
supernatant, a PBS wash was performed and then a further centrifugation process carried out. A lysis 
buffer was created using radioimmunoprecipitation assay buffer (RIPA) and protease and 
phosphatase inhibitors at a ratio of 1:99. Once the supernatant was discarded the cell pellet was 
treated with 100-200μL of lysis buffer, depending on the size of the pellet. Each pellet was incubated 
for 5 minutes at room temperature prior to undergoing sonication for 5-10 seconds at 30% output 
with a continuous pulse. The treated cell pellet was then kept on ice and centrifuged at 4oC at 
20,000xg for ten minutes. The supernatant was collected and stored at 4oC once protein 
concentrations were calculated. The Pierce Bicinchonic Acid assay (BCA) concentration standards 
were placed onto a 96 well plate at a volume of 25μL. Protein samples were diluted at a ratio of 1:10 
and duplicated to ensure accuracy. 200μL of a supplied working reagent was added to each well and 
the plate was placed on a shaker for 30 seconds. A 30-minute incubation period was undertaken at 
37oC prior to absorbance measurements at 562nm on a plate reader. The protein concentrations 
were used to create a standard curve on SigmaPlot version 14 and each sample parameter was 
plotted in order to calculate protein concentrations in μg/ml.  
2.10  Western blot analysis 
 
Equipment & Reagents  
 
Tween-20      (Sigma-Aldrich) 
Mini-Protean TGX gels     (Bio-Rad Laboratories) 
Laemmli       (Bio-Rad Laboratories) 
β-mercaptoethanol     (Sigma-Aldrich) 
Precision Plus Protein Dual Colour   (Bio-Rad Laboratories) 
PageRuler Prestained Protein Ladder   (Thermo Fisher Scientific) 
Trans-Blot Turbo Transfer System    (Bio-Rad Laboratories)  
Trans-Blot Turbo Mini 0.2 µm PVDF Transfer Packs (Bio-Rad Laboratories) 
Clarity Western ECL Substrate   (Bio-Rad Laboratories) 
ChemiDoc Imaging System     (Bio-Rad Laboratories)  
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Buffers       
 
Phosphate buffered saline with Tween (PBST)  
Dissolve 10 x PBS tablets into 1 L d.H20, add 1 mL Tween20 (0.1% in final solution) 
 
Loading buffer (4X) 
Lamelli solution and 10X β-mercaptoethanol, made up to appropriate volumes for number of gels 
and volume of columns  
 
SDS-PAGE Running Buffer (10x): 
30.3 g Tris base, 144.0 g Glycine, 50 mL 20% SDS, 950 mL d.H20 
 
Blocking solution 
5% Dried milk in PBST solution 
 
Stripping buffer 
20ml SDS 10%, 12.5ml TRIS HCl pH 6.8 0.5M, 67.5ml ultrapure water & 0.8ml β-mercaptoethanol 
 
Western blotting was performed using ready-made 10 or 15 column any kD Mini-PROTEAN TGX gels 
from Biorad. 20μg of each protein sample was calculated in microlitres to be used for one column on 
a gel and a loading buffer composed of β-mercaptoethanol and Laemmli buffer (1:10 ratio) applied 
at a ratio of 1:4. Adding sterile water increased the volume of the mixture to 15μl. For multiple 
antibody gels a stock working solution of protein was developed. A protein ladder was always used 
for every experiment. The samples were heated to 90°C for 15 minutes and loaded into the gels 
described as above. The gels were placed into an electrophoresis tank using a running buffer diluted 
with water. The gels were electrophoresed at 300V for 13 minutes. The gels were then transferred 
to a nitrocellulose membrane using a Bio-Rad Trans-Blot Turbo Transfer System at standard settings 
for the particular molecular weight gels. Once transference was completed the membranes were 
removed and placed in a blocking solution for 4 hours. Primary antibody treatment was performed 
overnight at 4oC and all membranes were placed on a rocker. The primary antibodies are listed in 
Table 4 and the concentrations used diluted with blocking solution. The membranes were washed in 
PBST for five-minute intervals when the PBST solution was replaced for a total of six washes. The 
membranes were then treated with secondary antibodies specific to the primary antibody animal 
type for one hour at room temperature. Following another six-wash cycle with PBST, each membrane 
was probed for 5 minutes with an enhanced chemiluminescence (ECL) substrate containing 
peroxidase. Membranes were imaged using the ChemiDoc MP system to detect the luminescence of 
the specifically targeted secondary antibodies. These were performed at standard settings and 
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subsequent repeat procedures utilising optimal cumulative exposures for appropriate time settings. 
These membranes were then stripped using a stripping buffer at 38oC for 15 minutes. A re-probing 
process was undertaken to check consistent loading levels of the housekeeping protein β-actin. After 
three membrane washes with PBST, the primary antibody was applied for thirty minutes at room 
temperature, followed by three further PBST washes and probing with the secondary antibody for a 
further thirty minutes. Further images were carried out using the ChemiDoc MP system. The actual 
images were analysed using the Bio-Rad Image Lab 6.01 software where the ladder images were 
incorporated into the optimal western blots. The software allowed densitometry analysis of the 
original images and it was possible to normalise all results to the respective actin levels. The images 
presented are the whole ladder-incorporated images and bar graphs of the normalised 
densitometries. Multiple densitometries were compared with parent and resistant cells lines using a 
paired t-test using the program GraphPad Prism version 8 for MacOS. 
 
Antibody Company (code) Animal Concentration 
RRM1 Proteintech (10526-1-AP) Rabbit polyclonal 1:1000 
RRM2 Abcam (ab57653) Mouse monoclonal 1:1000 
RRM2B (p53R2) Abcam (ab8105) Rabbit polyclonal 1:2000 
CDKN1A (p21) Cell Signal Tech (12D1) Rabbit polyclonal 1:1000 
Chk1 Cell Signal Tech (2360S) Rabbit polyclonal 1:1000 
CCND1 (Cyclin D1) Santa Cruz (H-295) Rabbit polyclonal 1:1000 
ß-Actin Sigma Aldrich (A5441) Mouse monoclonal 1:20000 
 
 
Table 4  A list of antibodies used in western blotting with native animal and concentrations. 
All secondary antibodies were tailored to the primary animal at a 1:3000 concentration 
 
2.11  RNA interference experiments 
 
Equipment & Reagents  
 
Various siRNA       (Dharmacon Inc.) 
Sterile RNAse free water     (Qiagen) 
Lipofectamine 2000     (Thermo Fisher Scientific) 
 
Gene knockdown studies were performed in order to determine effects on gemcitabine resistance, 
through MTS assays. Optimisation and time course studies were performed in order to assess degree 
of knockdown via western analysis. These were performed by utilising sterile 6-well plates and cells 
were seeded at 1x105 density in 2ml of stock RPMI media. After 24 hours each well was treated with 
small interfering RNA (siRNA): RRM1, RISC-FREE and Off-Target control and a lipofectamine only 
control. The siRNA that was obtained was suspended in sterile RNAse free water to produce a 20μM 
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stock. An RNA interference regimen for a single well of a 6-well plate consists of 3μl Lipofectamine 
2000 combined with 200μl of reduced serum Opti-MEM media incubated at room temperature for 
five minutes. 3μl of the specific siRNA was added to the media and flicked in order to mix the 
reagents, and then incubated at 37oC for thirty minutes. This mixture was then added to the seeded 
cell well, drop by drop swirling the plate. A time course experiment was performed at 24, 48, and 
72hrs to ensure competent knockdown of the required proteins and satisfactory control parameters. 
After the allotted time course, the media was stripped and washed with 2ml of PBS and the cells were 
either scraped using a cell scraper or dissociated using trypsin prior to following the protein 
extraction protocols and western analyses.  
 
A similar protocol was performed for a knockdown study on a 96 well plate. Cells were seeded as per 
previous MTS studies (as above) and an additional 24hr time period was allowed for siRNA treatment. 
Adjustments to the knockdown regimen were made based upon 96-well surface growth area. Stock 
regimens consisted of 10μl siRNA, 10μl of Lipofectamine 2000 and 650μl of Opti-MEM and 7μl was 
added to each well of a 96-well plate. After a 24hr time period the MTS protocol was followed as 
described above.  
 
2.12  cDNA transfection experiments 
 
Equipment & Reagents  
 
Tranfection ready cDNA    (OriGene Technologies Inc.) 
Lipofectamine 2000     (Thermo Fisher Scientific) 
 
DNA plasmid transfection studies were performed in order to determine effects on gemcitabine 
resistance, through MTS assays. A 24hr time course study was performed in order to assess degree 
of protein levels via western analysis. These were performed by utilising sterile 6-well plates and cells 
were seeded at 1x105 density in 2ml of stock RPMI media. Transfection ready cDNA was purchased 
from Origene with the RRM1 insert in a pCMV6-entry mammalian expression vector as a 10μg stock 
made to a 100ng/μl. A transfection protocol was used using 1-5μg of cDNA per well of a 6-well plate 
and 5-250ng per well of a 96-well plate. For the 24hr protein expression experiment each 6-well plate 
was treated with 1μg of cDNA. Prior to treatment, the transfection solution was prepared by adding 
the cDNA to 200μl of Opti-MEM and rested for five minutes prior to adding 3μl Lipofectamine 2000. 
This was incubated for thirty minutes and then added to a single well of a 6-well plate, drop by drop, 
swirling in the process. A lipofectamine control and empty plasmid was also used for these 
experiments. After the allotted time course, the media was stripped and washed with 2ml of PBS and 
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the cells were either scraped using a cell scraper or dissociated using trypsin prior to following protein 
extraction protocols and western analyses. 
 
A similar protocol was performed for a transfection study on a 96 well plate. Cells were seeded as 
per previous MTS studies and an additional 24hr time period was allowed for siRNA treatment. 
Adjustments to the transfection regimen were made based upon 96-well surface growth area. Stock 
regimens consisted of 10μl cDNA, 3μl of Lipofectamine 2000 and 2ml of Opti-MEM and 10μl was 
added to each well of a 96-well plate. After a 24hr time period the MTS protocol was followed as 
described above. 
 
2.13  Cell sorting experiments  
 
Fluorescence activating cell sorting (FACS) experiments were performed using propidium staining 
and a Thermofisher Attune NxT flow cytometer. Cell lines were treated with a median IC50 dose (of 
all IC50s) of gemcitabine (50nM) or a high dose of gemcitabine (250nM) for 48 hours prior to fixation 
and staining. A repeat set of experiments were performed on all cell lines with an additional 
parameter of collecting all cells, including those detached and within the supernatant.  
 
Specific Equipment and Reagents  
 
Attune â NxT Flow Cytometer  (Thermo Fisher Scientific)  
Propidium Iodide     (Sigma-Aldrich) 




2.13.1  Cell fixation and DNA staining 
 
All treatment parameters and cell lines were seeded at 1x105 onto a 6-well plate in stock RPMI media 
and allowed to adhere overnight. The cells were treated for 48 hours with gemcitabine by the 
addition of a calculated dose of the drug. After the treatment time the culture medium was removed 
and the cells washed in 1ml of PBS. 100μl of trypsin was then applied to dissociate the cells and 900μl 
of media was used to neutralise after a few minutes. The cells were then placed into a collection tube 
and centrifuged at 100xg for five minutes at 4oC. Where appropriate the supernatant was preserved 
and kept separately, and then combined with the dissociated cells and centrifuged together. Two ice 
cold PBS washes were performed and PBS aspirated leaving the remaining pellet. The final 
centrifugation was sometimes repeated in order to ensure all PBS was removed. The cells were 
vortexed at a low speed and cold 70% ethanol was added to the cells in a dropwise fashion. These 
cells were kept on ice for at least one hour to ensure fixation.  
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The staining process was performed using propidium iodide at a concentration of 10μg/ml. The cells 
were centrifuged at 200-300xg for five minutes to remove the ethanol, and a 5ml PBS wash with 
0.05% Tween-20 was carried out. After discarding the supernatant, the cells were re-suspended in 
0.5-1ml of PBS with 0.05% Tween-20 and 10μg/ml propidium iodide with 0.1mg/ml RNAse A. This 
was left at room temperature for at least an hour prior to analysis.  
 
2.13.2  Flow Cytometry  
 
The Thermofisher Attune NxT flow cytometer was used for cell cycle analysis incorporating the blue 
laser that functions at 488nm wavelength. All samples were tested at the same settings and a 
threshold of 10,000 events was used. Data was analysed using FCS Express 7 for MacOs, from De 
Novo software and each data set was analysed in the same manner to ultimately produce a histogram 
of count against cell area. The gating was performed on a cell area vs height scatter plot to exclude 
aggregates and debris. The software in-built modelling program allowed analysis of the normal 
distributions of G1 and G2 curves and the S-phase population. These percentages are displayed as 
bar graphs in the results sections.  
 
2.14  Neutral Comet Assay 
 
Equipment & Reagents  
 
CellRad X-Ray Irradiator    (Precision X-Ray Inc.) 
Normal melting point agarose (1 %) in dH2O  (Thermo Fisher Scientific)  
Low melting point agarose (1 %) in PBS  (Thermo Fisher Scientific) 
SYBR Gold 1 in 10,000 in dH2O, pH 8.0  (Thermo Fisher Scientific) 
Buffers       
 
Lysis Buffer  
 
800ml dH2O, NaCl (146.1 g, 2.5 M), EDTA disodium salt (37.2 g, 100 mM), Tris base (1.2 g, 10 mM), 
1% N-lauroylsarcosine (10 g), at pH 9.5 (using NaOH (8g) and 5M NaOH)  
Adjusted to 1 L and stored at 4°C. Working solution completed using 1 ml DMSO and 1 ml Triton X-
100 to 98 ml cold lysis buffer 
 
Electrophoresis Buffer (5X) 
 
800ml dH2O, 54 g Tris base, 27.5 g boric acid, 20 ml of 0.5 M EDTA (pH 8.0) 
This was adjusted to a pH of 8.3 and a volume of 1L and stored at toom temperature.  
Working solution of 1.5L consisted of 300ml of 5X buffer with 1.2L of distilled water  
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A neutral comet assay was performed in order to assess double strand DNA damage. Treatment 
parameters included low dose gemcitabine (50nM) treatment and high dose treatment (250nM) with 
negative controls and irradiated cells as positive controls. Slides were prepared by placing 800μl of 
normal melting point agarose gel, covered with a coverslip. Once set, the coverslips were removed 
and the slides left to dry overnight. There were two technical replicates and two biological replicates 
of every cell and treatment parameter. All cells were cultured and treated in the exact same way as 
in section 2.12.1 and dissociated and neutralised with trypsin and stock RPMI media. A 250μl volume 
of cells was placed onto the pre-prepared slides and 1ml of low melting point agarose gel placed atop 
with a coverslip. These slides were placed on ice for two minutes. For the positive control cell lines, 
the cell suspension was placed into a 24-well plate and irradiated at 8Gy using a CellRad X-Ray 
Irradiator. These were then placed on the pre-prepared slides as described above. After two minutes 
all slides had the coverslips removed and placed into Coplin jars containing fresh cold lysis buffer. 
The jars were left overnight and then washed twice in cold electrophoresis buffer. The slides were 
transferred to a black horizontal electrophoresis tank and covered in cold electrophoresis buffer for 
30 minutes to allow DNA to unwind. The slides were then electrophoresed at 25V (~20 mA) for 25 
minutes. Slides were removed and washed twice in PBS buffer for five minutes. Slides were dried 
overnight and then rehydrated in distilled water for thirty minutes. SYBR Gold nucleic acid stain was 
diluted in distilled water to give a 1X concentration and 1ml applied to each slide for thirty minutes. 
Excessive fluid was shaken off and slides were then allowed to dry prior to analysis. Each slide was 
imaged using a fluorescence microscope and ten images were taken per slide. The Komet 6.0 image 
analysis software (Andor technology) was used to quantify DNA of the comets. The software gives a 
percentage proportion of total DNA in the tail of the comet once the head and tail were manually 
located. Five readings per image were taken, giving fifty results. There were two biological and two 
technical replicates giving a total of two hundred readings per cell treatment parameter. Statistical 
comparison between parent and resistant cells were compared using unpaired t-test using Welch’s 
correction with the program GraphPad Prism version 8 for MacOS. A single slide representative image 
is given for all treatment parameters in the results section.  
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3.  Results   
 
3.1 Generation of gemcitabine resistant cell lines 
 
The development of gemcitabine resistant pancreatic cell lines was carried out using the two 
separate methods outlined in the Materials and Methods. The established pancreatic cancer cells 
lines, Suit-2 and Panc-1 were employed to generate resistant cell lines. Table 5 depicts the cells lines 
created: Four clonally resistant Suit-2 lines and one clonally resistant Panc-1 cell line and one 
adaptively resistant Suit-2 line.  
 
During the development of the clonally resistant Suit-2 cell lines, replenishing the gemcitabine 
treatment by adding a further concentration of the drug to the individual wells of a 96-well plate was 
attempted twice a week. The single cells that underwent mitosis subsequently became necrotic and 
the islands of cells diminished and thus this element of the design was abandoned. Developing 
adaptive resistance was more straightforward; Suit-2 cells rapidly grew in T75 flasks containing 
culture medium with additive gemcitabine. Fifteen cell passages were performed in both Suit-2G+ 
and Suit-2G- prior to any experimentation to test the relevance of gemcitabine infused culture 
medium in Suit-2G+ compared to normal drug free media in Suit-2G-.  
 




  - 
Table 5 Depicting the types of resistant cell lines developed from the two parent immortalised 
pancreatic cancer cell lines  
 
 
In order to confirm resistance, MTS cell viability assays were performed on all cell lines. A drug dose 
response curve was calculated and the concentration of gemcitabine that induced a 50% reduction 
in cell viability (IC50) was calculated. Representative examples of MTS assays are demonstrated in 
Figures 5-7 with IC50 results in Table 6. The gemcitabine IC50 of the Suit-2 cell line is 10.1nM and the 
clonally resistant lines, Suit-2R to Suit-2R4 had readings of 24.3nM, 22.8nM, 86.7nM and 52.7nM 
respectively. The Panc-1 cell line had an IC50 of 15.4nM and the clonally resistant Panc-R IC50 was 
61.7nM. The Suit-2G cell lines show a clear dependence on gemcitabine to maintain resistance. The 
Suit-2G+ cell line was maintained in culture medium with 500µM of gemcitabine and additional MTS 
experiments fail to show a decrease in viability in concentrations up to 100μM of gemcitabine. This 
is shown in figure 6; with no appreciable drug dose response given the normalisation process 
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(minimal absorbance 1.97 and maximum absorbance 2.32). Within the same figure, the Suit-G- curve 
closely follow the Suit-2 curve with a 2nM difference in gemcitabine IC50s. This contrasts with the 
Suit-2R, Suit-2R2, Suit-2R3, Suit-2R4 cell lines that are cultured in gemcitabine free medium that 





















Figure 5  A cell viability MTS assay of Suit-2 and clonal resistant cell lines demonstrating the 
gemcitabine resistance of each cell line. The absorbance on the y-axis was normalised to a value 
between zero and one to allow direct comparison of the best fit non-linear regression curve. Exact 
IC50 readings are shown in Table 6 







































Figure 6  A cell viability assay of Suit-2, Suit-2G and Suit-2G- to demonstrate resistance to 
gemcitabine. The absorbance on the y-axis was normalised to a value between zero and one to allow 
direct comparison of the best fit non-linear regression curve. The Suit-2G+ line does not reach a 50% 
reduction in viability and the linear regression model demonstrates this. Compared to the Suit-2G- 
best fit non-linear curve that has almost returned to the parent Suit-2 gemcitabine sensitivity. Exact 




Figure 7  A cell viability assay of Panc-1 and Panc-R to demonstrate resistance. The absorbance 
on the y-axis was normalised to a value between zero and one to allow direct comparison of the best 
fit non-linear regression curve. Exact IC50 readings are shown in Table 6 
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3.2  Description of resistant cell line growth  
 
Using the MTS assays described above, the control wells of the 96 well plate represent the standard 
growth of the cell lines for 72hrs. Prior to normalisation of the MTS absorbance levels, the reduction 
in growth rate in the Suit-2R cell line is apparent in Figure 8. It also shows similar growth rates of all 
other Suit-2 lines and the expected slower rate of Panc-1 cells. The resistant Panc-R line has a growth 
rate comparable to its parent line. In the case of Suit-2R the reduction in growth rate may be pertinent 
to its mechanism of gemcitabine resistance. Though this is an informal study for investigating growth 
rates, it highlights significant findings related to resistant cell characteristics.  
 
 
Figure 8 A cell viability assay depicting the control parameter of the drug response assays 
carried out in figures 5-7. The absorbance result is a 96-hour snapshot of cell growth and demonstrates 
the expected lower rates of Panc-1/Panc-R cells compared to Suit-2 and the slower growth rate of 
Suit-2R cells compared to the parent line   
 
With the establishment of resistant cell lines and the slower growth rate of Suit-R, there is potentially 
more than a single mechanism conferring resistance to these cell lines. The effects of gemcitabine 
may be mitigated in order to maintain a degree of cell growth in the presence of the chemotherapy 
agent.  Various studies have indicated that the phosphorylation process of the inactive form may play 
a role in sensitivity. Due to lack of consistent and reliable human equilibrative nucleoside transporter 
1 (hENT1) antibody and non-significant findings in RNA expression of deoxycytidine kinase (DCK) and 
cytidine deaminase (CDA) across all cell lines, no further experiments on the intra-cellular activation 
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3.3  Investigating the cytotoxic effects of gemcitabine  
 
It has been widely reported that gemcitabine causes a stalling of the DNA replication fork and induces 
double strand breaks (DSB) and the neutral comet assay quantifies the level of DSB in individual cells. 
Following DNA damaging conditions, cells are embedded in agarose gel on a slide, then 
electrophoresed in the presence of a fluorescent intercalating agent (ethidium bromide). DNA 
fragments migrate faster than cells and these fragments will form a ‘tail’ of DNA emanating from 
each cell. The length and intensity of the tail indicates the level of damage; another form of this assay 
involves denaturing of the DNA with basic conditions and so will also detect single strand breaks. 
The negative drug free control arms of the experiment depict the baseline degree of DSB of the 
experimental process. Whereas the positive control cells are subjected to DNA damage from 8Gy 
radiation, a commonly used experimental and clinical dose. These afford suitable comparators to 
experimental parameters of gemcitabine exposure at an average of the IC50s of all resistant cell lines 
(50nM) and a higher dose of the drug (250nM). Figure 9 is a collection of representative images of 
each parameter slide and demonstrates the comets and the tail lengths of all clonally resistant Suit-
2 cells. The DSB figure is a surrogate indicator of percentage DSB using the tail DNA proportion 
compared to the head DNA. The mean percentage of DNA DSB per treatment paradigm is 
documented within the table of that figure. A box and whisker plot for every experimental parameter 
is shown in figure 10 including cell line comparisons at 50nM and 250nM of gemcitabine treatments. 
Additional bar graphs are presented in order to compare the proportional increase of DSB compared 
to each cell line baseline. At 50nM of gemcitabine all cell lines have significantly less DSBs compared 
to the parent line but only Suit-2R and Suit-2R4 have significantly less damage at a dose of 250nM. 
Despite having less DSB DNA damage, the clonally resistant cell lines still undergo the cytotoxic 
effects of gemcitabine. Comparing the DSB proportion to the control of each cell, there are still DSB 
in all resistant clones at 50nM (figure 10h): Increases from baseline of 31% for Suit-2R and 18% for 
Suit-2R3 compared to 92% for the parent strain. Suit-2R2 actually had an increased percentage of 
double strand breaks greater than the parent (116% increase) and Suit-2R4 had a 74% increase at 
50nM. Notably none of the resistant cell lines showed any resistance to DSB induced by gamma 
radiation (figure 10j). Indeed, all had a greater increase in DSB following gamma radiation than even 
the parent: Suit-2R4 having a 480% increase, Suit-2R2 and Suit-2R3 having over 400% increases and 
even Suit-2R having a 370% increase (compared to a 300% increase in the parent strain). This implies 
that in all cell lines, resistance cannot be explained specifically to DSB prevention from gemcitabine. 
Only Suit-2R demonstrates comparatively consistently low levels of DSB which may be due to a 
holistic resistance as opposed to specifically to the cytotoxic element of gemcitabine or improved 
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DSB repair processes. It is more apparent that the cell lines are able to mitigate the effects of DSB 













































Figure 9  Representative comet images are shown for Suit-2, Suit-2R, Suit-2R2, Suit-2R3 and 
Suit-2R4 cell lines at different doses of gemcitabine and positive and negative controls. The longer the 
tail of the comet, the higher the proportion of DSB in the cell. The tables provide the mean proportion 
of DNA in the comet tails with each treatment. Each resistant line has a lower DSB percentage at 
50nM of gemcitabine but only Suit-2R4 maintains low at 250nM  
Parameter/Cell line  Suit-2 Suit-2R Suit-2R2 Suit-2R3 Suit-2R4 
Control  6.6 7.0 5.0 7.9 5.0 
50nM gem  12.7 9.2 10.8 9.3 8.7 
250nM gem  20.1 16.4 19.9 22.1 10.8 
8Gy radiation  26.1 32.7 26.5 42.0 29.2 
Treatment 
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a) Suit-2      b)   Suit-2R             c)   Suit-2R2 
 
        




            f)   50nM Gemcitabine treatment             g)   250nM Gemcitabine treatment   
 
 
Figure 10  Box and whisker plots to show the median, interquartile range and maximum and 
minimum DNA DSB percentages of Suit-2, Suit-2R, Suit-2R2, Suit-2R3 and Suit-2R4 cell lines at 
different treatment parameters (a-e). Figures (f) and (g) compare DSB % of each cell line at 50nM and 
250 nM gemcitabine treatments, * p<0.05. This demonstrates the significantly lower DNA DSB 
damage at 50nM of gemcitabine in all resistant lines compared to the parent, but this is only 
maintained in Suit-2R and Suit-2R4 at a higher concentration of gemcitabine. Figures (h)-(j) 
demonstrate relative percentage change compared to control at each treatment parameter and show 
Suit-2R2 has higher DSB compared to even the control at 50nM and all cells sustain more damage at 
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These effects are not seen clearly in the Suit-2G cell lines where figures 11 and 12 show Suit-2G+ cells 
have a significantly lower DSB proportion compared to Suit-2 and Suit-2G-. There is no discernible 
difference in percentage DSB damage between no treatment (7.8%) and 50nM gemcitabine 
treatment (6.6%) in Suit-2G+, but it does increase to 13.5% at the higher dose. Comparing this to Suit-
2 and Suit-2G-, where an increase of 5.5% and 5.8% respectively is seen when treating with 50nM 
gemcitabine and 12.8% and 11.8% respectively with 250nM of gemcitabine. Figure 12f-h expand 
further these findings and show Suit-2G+ cells have proportionally less DSB compared to the control 
(-15% vs 71% at 50nM and 73 vs 164% at 250nM) and this may be explained by specific resistance to 
DSB or a specific response in DNA repair processing, bearing in mind that at 8Gy there are still 
significant proportion of double strand breaks. Suit-2G- cells are markedly different to Suit-2G+ and 
have increases of 89% and 181% DSB at 50nM and 250nM gemcitabine with less (148%) at 8Gy 
radiation. Once exposure to gemcitabine is removed, the repair processes instigated in Suit-2G+ may 
still persist and explain why at 8Gy it suffers the least amount of DSB in all experimental cell lines.  
 
This further strengthens the observation that suspending gemcitabine infused culture medium 
returns sensitivity to gemcitabine to Suit-2G+ cells. This implies that the mechanisms to counteract 
gemcitabine induced replicative stress, which is still present at a lower level in Suit-2G+ cells, are 





































Figure 11  Representative comet images are shown for Suit-2, Suit-2G+ and Suit-2G- cell lines at 
different doses of gemcitabine and positive and negative controls. The longer the tail of the comet, 
the higher the proportion of DSB in the cell. The tables provide the mean proportion of DNA in the 
comet tails with each treatment. At both gemcitabine treatments, there is a similar DNA DSB % of 
Suit-2G- and Suit-2 cells, whereas it is a lower percentage in both with Suit-2G+ cells.   
 
     a)   Suit-2                                             b)     Suit-2G+               c)     Suit-2G- 
 
 












































































Parameter/Cell line  Suit-2 Suit-2G+ Suit-2G- 
Control  7.8 7.8 6.5 
50nM gem  13.3 6.6 12.3 
250nM gem  20.6 13.5 18.3 
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d)   50nM Gemcitabine treatment            e)   250nM Gemcitabine treatment 
   
 
 
Figure 12  Box and whisker plots to show the median, interquartile range and maximum and 
minimum DNA DSB percentages of Suit-2, Suit-2G+, Suit-2G- cell lines at different treatment 
parameters (a-c). Figures (d) and (e) compare DSB % of each cell line at 50nM and 250nM gemcitabine 
treatments, * p<0.05. This demonstrates the significantly lower DNA DSB damage at 50nM and 
250nM gemcitabine treatments in Suit-2G+ cells but this effect is not shown in Suit-2G- cells. Figures 
(f)-(h) demonstrate relative percentage change compared to control at each treatment. Note the y-
axis have variable maximum levels. Suit-2G+ has marked reduction in DSB when treated with the drug 
compared to Suit-2 but still has large DSB at 8Gy. Whereas Suit-2G- cells not returned to control levels   
 
  f) 50nM gemcitabine treatment        g) 250nM gemcitabine treatment      h) 8Gy radiation treatment 
    
 
Figures 13 and 14 show Panc-1 and Panc-R comet assays and box plots. They demonstrate the 
significantly lower proportion of DSB of the clonally resistant cell line, but only at a higher dose of 
gemcitabine. At 50nM the DNA damage is 8.6% and 7.6% in Panc-1 and Panc-R cells respectively but 
at 250nM there is a significant difference because the resistant line remains low at 6.8% compared 
to 11.5% in the parent line. When comparing to the control of each cell line, there is proportionally 
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There are similar DSB proportions at 8Gy of approximately 350% implying that Panc-R may have 





























Figure 13  Representative comet images are shown for Panc-1 and Panc-R cell lines at different 
doses of gemcitabine and positive and negative controls. The longer the tail of the comet, the higher 
the proportion of DSB in the cell. The tables provide the mean proportion of DNA in the comet tails 
with each treatment. At both gemcitabine treatments, there is lower DNA DSB % in Panc-R cells 
compared to the parent Panc-1  
 





















































Parameter/Cell line  Panc-1 Panc-R 
Control  4.7 4.5 
50nM gem  8.6 7.6 
250nM gem  11.5 6.8 
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Figure 14  Box and whisker plots to show the median, interquartile range and maximum and 
minimum DNA DSB percentages of Panc-1 and Panc-R cell lines at different treatment parameters 
(a,b). Figures (c) and (d) compare DSB % of each cell line at 50nM and 250nM gemcitabine treatments, 
* p<0.05. This demonstrates the significantly lower DNA DSB damage at 250nM gemcitabine 
treatment in Panc-R cells compared to Panc-1, this effect is not seen at the lower dose. Figure (e) 
demonstrates relative percentage change compared to control at each treatment parameter. The 
Panc-R line demonstrates proportionally similar increase in DSB compared to its control, except at 
250nM where there are more DSB   
 
          c)     50nM gemcitabine treatment            d)     250nM gemcitabine treatment 
 
 
         50nM           250nM                 8Gy 
 
The comet assay experiments have demonstrated that DNA damage remains the cytotoxic effect of 
gemcitabine, albeit it at a higher concentration in the clonally resistant cell lines compared to the 
parent Suit-2 and Panc-1 cell lines. This would indicate that a repair mechanism has developed that 
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specifically to gemcitabine or an overall improvement in DSB repair functions. There is not a 
comparator of clonally isolated cells grown without gemcitabine, in conjunction with the resistant 
clones. The clonally resistant cells may overcome DSB to continue to grow whereas as Suit-2G+ may 
have a holistic process to improve DNA repair, given Suit-2G- has less damage at 8Gy and Panc-R may 
have a specific gemcitabine compensation processes. There is variation with all three groups of 
resistant cell lines and builds the evidence base of a complex varied set of resistance mechanisms. 
 
DNA damage and repair are closely related to the cytostatic effect of gemcitabine. It provides an 
inhibitory function to ribonucleotide reductase which is responsible for the supply of 
deoxyribonucleotides, essential for DNA synthesis. In order to full elucidate the processes of 
gemcitabine resistance, the function of the ribonucleotide reductase (RR) complex and its effect on 
DNA repair requires establishing.  
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3.4  Investigating the cytostatic effects of gemcitabine  
 
The ribonucleotide reductase complex is a heterodimeric tetramer comprising of RRM1 and RRM2 
subunits with the p53 inducible p53R2 being able to pair with RRM1 in the place of RRM2. The 
following sections review the RNA fold change and protein levels of each of these sub-units in order 




Figure 15 shows the fold change in RNA expression of RRM1 in all cell lines. They are plotted 
separately because the Suit-2G+ cell line has a mean 85-fold increase in RRM1 RNA expression and 
obscures the graphical representation of smaller changes. This effect is not as prominent in the Suit-
2G- cell lines but there is still a 14-fold increase in RRM1 RNA. There are smaller increases in the Suit-
2R and Panc-R cell lines but there is a large standard deviation from the mean, inferring there is likely 
to be no difference. Suit-2R2, Suit-2R3 and Suit-2R4 have reduced mean RRM1 RNA expression with 
fold changes of 0.67, 0.36 and 0.42 respectively. Figures 16 and 17 demonstrate the impact of altered 
RRM1 RNA production on protein translation.  
 
  a)     Suit-2R cell lines                     b)     Suit-2G cell lines     c)    Panc-1 cell lines 
 
 
Figure 15 Bar charts to demonstrate the mean fold change of RRM1 RNA expression in a) Suit-2 
and the clonally resistant cell lines b) Suit-2 and the adaptively resistant Suit-2G cell lines c) Panc-1 
and Panc-R. Each dot represents an experimental replicate and mean and standard errors are plotted 
for each cell lines. There is a decrease in RNA expression in Suit-2R3 and Suit-2R4 which is not seen in 
Suit-2R and Suit-2R2 (a). This contrasts with the significant fold change increase in the RRM1 RNA 
expression of Suit-2G+ cells and a smaller but persistently high increase with Suit-2G-. There is a two-
































































Figure 16 A representative western blot to show the expression of the RRM1 protein at the 
expected molecular weight of 90kDa, with the housekeeping protein b-actin at the base of the blot. 
Suit-2R and Suit-2R4 show reduced protein RRM1 expression where Suit-2R2 and Suit-2R3 show the 
converse. The Suit-2G+ has an overwhelming increase in RRM1 expression and Suit-2G- has a smaller 
increase compared to Suit-2. This effect is also seen with Panc-R in comparison to Panc-1  
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Figure 17 A dot plot depicting the mean and standard error of every RRM1 experimental 
densitometry normalised to actin levels of the a) Suit-2 and Suit-2R b) Suit-2G+ and Suit-2G- c) Panc-
1 and Panc-R cell lines, *<0.05. The increase in RRM1 protein levels seen in Suit-2R2 and Suit-2R4 were 
statistically significant as were the decreases in expression in the Suit-2R and Suit-2R4 cell lines. The 
marked increase in Suit-2G+ was statistically significant as was the change in RRM1 protein levels in 
Suit-2G- compared to the parent line. This increase was also reported with the Panc-R cell line 
compared to the parent Panc-1 cell line  
 
    b)     Suit-2G cell lines               c)     Panc-1 cell lines 
 
               
 
Figure 16 is a complete representative western blot of the RRM1 antibody and has been divided into 
sections to allow ease of comparison to parent lines, with the Suit-2 column being duplicated 
adjacent to the Suit-2G lines. It shows that Suit-2R and Suit-2R4 are cell lines with reduced RRM1 
protein level compared to Suit-2, and Suit-2R2 and Suit-2R3 have increased RRM1 expression. This is 
confirmed statistically in figure 17a where all western experiments are plotted and significant 
differences are found in every clonally resistant line. Panc-R has a significantly higher expression of 
RRM1 compared to Panc-1, similar to Suit-2R2 and Suit-2R3. Suit-2G+ has an overwhelming increase 
in RRM1 protein level with a smaller increase in the Suit-2G- cell line compared to the parent Suit-2. 
These effects appear to be driven from an epigenetic level as the RNA fold changes are similarly 
increased as shown in figure 15b. This cannot be said about the clonally resistant Suit-2 and Panc-1 
lines where figures 15a and 15c do not show significant changes in RNA expression, except that Suit-
2R3 and Suit-2R4 where it is reduced. There is likely to be a post transitional modification because 


















































The same RRM2 antibody was used throughout western analyses and in some instances two bands 
occurred. Although both bands were believed to be RRM2 (the faster moving band may have a 
modification e.g. phosphorylation) only the dominant band was included in the comparison between 
cell lines and conditions. Combining the bands was considered unsafe (it is unclear whether the 
relationship between staining intensity and concentration was the same for both) and any 
comparison based on the two bands would force assumptions that could not be supported 
experimentally. Changes to the intensity of the dominant band were chosen as measures of changes 
in RRM2 (which could have involved changes post-translationally or of total protein level). 
Figure 18 shows the fold change in RNA expression of RRM2 in all cell lines and depicts that Suit-2R 
and Suit-2R4 have subtle increased in mean RNA expression, 1.2 and 2.3-fold respectively. There are 
decreases in mean RRM2 RNA expression in Suit-2R2, Suit-2R3 and the Panc-R lines of 0.17, 0.36 and 
0.38-fold respectively. There is no appreciable change to the Suit-2G cell lines.  Figures 19 and 20 
demonstrate an analysis of the protein level of RRM2 and it is worth noting that there are not 
significant changes and after statistical analysis of all blots, only Suit-2R had reduced expression. The 
potential increases in RNA expression with Suit-2R, Suit-2R4, Panc-R may not translate to any 
substantial changes at a protein level. There may be a post translation regulation in Suit-2R cell lines 
but levels are still only slightly deviated from the parent cell line. It is worth noting that despite 
massive increases of RRM1 RNA and protein level, this does not correlate with similar RRM2 findings, 
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Figure 18 Bar charts to demonstrate the mean fold change of RRM2 RNA expression in all cell 
lines. Each dot represents an experimental replicate and mean and standard errors are plotted for 
each cell lines. There is a decrease in RNA expression in Suit-2R2 and Suit-2R3 which is not seen in 
Suit-2R and Suit-2R4 which may have the contrary effect. No fold change is apparent to RRM2 RNA 
expression in the Suit-2G lines & Panc-R exhibits a reduction in RNA expression compared to Panc-1     
 
Figure 19 A representative western blot to show the expression of the RRM2 protein at the 
expected molecular weight of 45kDa, with the housekeeping protein b-actin at the base of the blot. 
Both bands were included in the densitometry analysis. Suit-2R2 and Suit-2R4 show reduced protein 
RRM2 expression where all other cell lines show no change to the parent Suit-2 or Panc-1 cell line.  
 
Figure 20 A dot plot depicting the mean and standard error of every RRM2 experimental 
densitometry normalised to actin levels of all cell lines, *<0.05. The decrease seen in figure 19 of Suit-
2R2 and Suit-2R4 were not apparent after all western densitometries were reviewed, it is worth noting 





























































































The p53 inducible subunit of RR is p53R2 and figure 21 depicts the fold change in RNA expression in 
all cell lines. There may be similar trends in comparison to the RRM2 RNA expression. In the Suit-2 
clonally resistant lines where Suit-2R2 and Suit-2R3 show a reduced expression at a mean of 0.64 and 
0.61- fold change respectively. There are possible similarities with Suit-2R and Suit-2R4 with similar 
if not increased expressions but there is a wide error margin. With the two experimental replicates, 
there is a reduced mean fold change in Panc-R of 0.62 compared to Panc-1. Similar findings are found 
with the Suit-2G+ and Suit-2G- cell lines of 0.52 and 0.60 mean fold change.  
 
Figures 22 and 23 show the protein level of p53R2 and there are few differences to note. Of 
significance (though not statistically p=0.09) is the reduction in expression in Suit-2R4 cells of almost 
half the level of Suit-2 cells. In comparison to other resistant cell lines, the possible reduction in RNA 
expression does not correlate with any significant change at a protein level. There is clearly a 
difference with Suit-2R4 cells which may arise at a post-transcriptional stage.  
 
 
Figure 21 Bar charts to demonstrate the mean fold change of p53R2 RNA expression in all cell lines. 
Each dot represents an experimental replicate and mean and standard errors are plotted for each cell 
lines. There is a decrease in RNA expression in Suit-2R2 and Suit-2R3, the opposite effect is potentially 
seen in Suit-2R and Suit-2R4, but there is a high degree of error.  There are also some decreases to RNA 









































Kulbir Mann: Results 
 57 
 
Figure 22 A representative western blot to show the expression of the p53R2 protein at the 
expected molecular weight of 39kDa, with the housekeeping protein b-actin at the base of the blot. 
Suit-2R4 is the only cell line that exhibits any difference, a reduction in the protein level of p53R2 
 
 
Figure 23 A dot plot depicting the mean and standard error of every p53R2 experimental 
densitometry normalised to actin levels of all cell lines, *<0.05. The decrease seen in figure 22 of Suit-
2R4 is apparent with a low degree of error. This did not reach statistical significance with a p-value of 
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Reviewing the RR complex on the whole, RRM1 appears to play the key role in its function as there 
are significant changes in almost all cell lines. Whether there is reduced expression at a protein level 
(Suit-2R and Suit-2R4) or an increase (Suit-2R2, Suit-2R3 and Panc-R) these may arise from epigenetic 
modification that occur after DNA transcription. The opposite effect is seen with the adaptively 
resistant cell line Suit-2G+ where an 85-fold increase in RNA expression correlates directly with the 
massive increase in protein level, which subsequently decrease at both stages once gemcitabine 
stimulus is removed from cell culture (Suit-2G-).  
 
These findings are not apparent with the small subunit of RR, even at the recruitable p53R2 level. 
There are some changes at translational levels, most likely reduced in Suit-2R2, Suit-2R3 and Panc-R 
but these do not correlate with any significant change at a protein level. Suit-2R2 and Suit-2R4 
demonstrate reduced RRM2 and p53R2 protein level respectively but this does not correlate with an 
increase in its substitute protein.  
 
Though the RR complex is formed from the RRM1 and either the RRM2 or p53R2 subunit, it is the 
larger RRM1 which may play a determining role in tampering with the cytostatic effects of 
gemcitabine. The following section explores this further by altering the expression of RRM1 to 
determine whether resistance to gemcitabine is affected.   
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3.5  Assessing gemcitabine resistance through RRM1 modifications  
 
This section observes RRM1 expression in various experimental conditions. Given its low level and 
high-level expression in the clonally resistant cells lines, siRNA was used to perform RRM1 RNA 
interference to reduce expression and RRM1 plasmid transfection was performed to increase RRM1 
expression. In the initial instance it was pertinent to elicit the cells response, specifically to RRM1, 
upon treatment with gemcitabine.  
 
3.5.1 The effect of gemcitabine treatment on RRM1 expression 
 
Figure 24 show western blots to observe the expression of RRM1 when the cells are treated with 
gemcitabine for 48hrs. The two gemcitabine doses are similar to above experiments and represent 
the average IC50 of the resistant cells (50nM) and a suitably high dose (250nM). 
  
a)     Suit-2 and clonally resistant lines 
 
Figure 24 A western blot to show the expression of the RRM1 protein at the expected molecular 
weight of 90kDa with treatment parameters of 50nM and 250nM of gemcitabine compared to a 
control line of a) Suit-2 and clonally resistant lines and b) Suit-2G+, Suit-2G- and Panc-1, Panc-R. the 
parent cell lines of Suit-2 and Panc-1 demonstrate an increase in RRM1 protein level at the mean IC50 
of gemcitabine in resistant lines and then a decrease below that of the control. This effect is seen in 
Suit-2R and Suit-2R2. The respective increases occur to the untreated control of the particular 
resistant line as the levels of RRM1 expression in each line are consistent with previous findings. This 
trend is similar with Suit-2R4, Suit-2G+ and Suit-2G- cells except quite marked increases exist in RRM1 
expression and at a higher dose the levels do not drop to that of the untreated control. Suit-2R3 cells 
exhibit no such increase and there is a reduction in RRM1 expression at both doses of gemcitabine. 
Panc-R cells exhibit a unique progressive increase with gemcitabine treatment, with the highest 
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a) Suit-2G+ and Suit-2G-, Panc-1 and Panc-R 
 
In general, the increase production of RRM1 to gemcitabine is expected in order to circumvent the 
cytostatic binding of gemcitabine to RRM1. In Suit-2R, Suit-2R2 and Suit-2R3 there is a reduction in 
RRM1 at the higher dose of gemcitabine, presumably because of the general toxic effect of nucleotide 
starvation rendering the cell incapable of producing RRM1. This is particularly apparent in Suit-2, Suit-
2R and Suit-2R2 where the RRM1 expression drops to less than untreated controls at 250nM of 
gemcitabine. With respect to Suit-2R4, Suit-2G+, Suit-2G- and Panc-1 all depict levels of RRM1 at 
250nM of gemcitabine higher than the control. These cell lines are able to maintain higher levels of 
RRM1 even at higher doses which may represent their higher IC50s compared to Suit-2R and Suit-
2R2. An interesting observation is the Suit-2G- cell line which maintains high levels of RRM1 but is no 
longer resistant to gemcitabine. Reviewing the comet analysis, it could be concluded that the cells 
are able to repair DSB but unable to overcome the cytostatic effects despite being able to produce 
high levels of RRM1. Suit-2R2 and Suit-2R4 which both have low levels of RRM1 show little response 
to gemcitabine treatment suggesting a different form of resistance and relationship to RRM1 
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3.5.2 The effect of RRM1 siRNA interference on gemcitabine resistance  
 
Figure 25 demonstrates a successful RRM1 knockdown after 24hrs of RRM1 siRNA treatment of the 
Suit-2 cell line. This blot also depicts RRM2 and p53R2 knockdown columns which were also analysed 
through cell viability assays. These knockdowns were successful but not demonstrated here because 
the MTS assays did show any change and are not be discussed further in this thesis. It should be noted 
that the additional RRM1 knockdown blots on all resistant cell lines were performed but are not 
available for this thesis. The MTS assays were of a four-day duration as opposed to three days 
because of the additional 24hr siRNA treatment required.  
 
There is considerable diversity amongst the cells when analysing the effect of the interference, with 
a decrease in growth rates except for Suit-2G+. There is a significant reduction in cell growth in Suit-
2R2, Suit-2R3, Suit-2G- and to a lesser degree in the remaining lines. This is worth bearing in mind 
when contemplating figures 27 & 28 and the drug dose curves and when trying to calculate IC50 





Figure 25 A western blot to show the expression of the RRM1 protein in Suit-2 cells at the 
expected molecular weight of 90kDa with treatment parameters of lipofectamine only, Off Target 
knockdown, RRM1 knockdown, RRM2 knockdown, p53R2 knockdown and RISC-Free knockdown. This 




















































Figure 26 A bar graph depicting the experimental control arm of the cell viability assay of all cell 
lines undergoing RRM1 knockdown, as part of the drug response in figures 27 & 28. The absorbance 
result is a 96-hour snapshot of cell growth and demonstrates the variability of rates between cell lines 
and the lower rate from this RRM1 knockdown procedure, except for the Suit-2G+ cell line  
 
Figures 27 and 28 show that RRM1 knockdown has a reduction in sensitivity (curve shifted to left) 
with respect to the Suit-2 parent cell line with no obvious effect in the Panc-1 parent. All the clonally 
resistant cell lines including Panc-R do not exhibit any obvious change to resistance as the curves do 
not deviate from the lipofectamine control, except for Suit-2R4. The curve has clearly shifted to the 
right with greater vitality at higher doses of gemcitabine, suggesting the resistance in Suit-2R4 is not 
necessarily solely based on RRM1 overexpression. There is clearly no resistance effect with respect 
to Suit-2G- but a decrease in growth rate is apparent in figure 26. Suit-2G+ is the only cell line that 
does not have an effect on viability with RRM1 knockdown and also surprisingly seems to have no 
impact on resistance. So, despite gemcitabine causing a dramatic increase in RRM1 levels, this does 
not appear to be the exclusive reason for the resistance. Note that the lipofectamine control has also 
demonstrated some loss of viability which needs to be taken into consideration when interpreting 
the data on siRNA. Although the conclusions above are based on relative effect of the RRM1 
knockdown against similarly treated cells.  
 
In summary the knockdown of RRM1 has a considerable effect on the growth rate of almost all cell 
lines which is expected given its role in providing nucleotides to DNA replication, and it also increases 

















































Figure 27  A cell viability assay of Suit-2 and clonally resistant cell lines Suit-2R, Suit-2R2, Suit-
2R3, Suit-2R4 comparing RRM1 knockdown to lipofectamine only control. The absorbance on the y-
axis was normalised to a value between zero and one to allow direct comparison of the best fit non-
linear regression curve. Figure 26 demonstrates the differences in growth rates of these cell lines 
which does make drug response curves more difficult to perform. In any case Suit-2 cells exhibit an 
increase in sensitivity with RRM1 knockdown, an effect not seen in any other cell line. Suit-2R4 
potentially exhibits an increase in resistance with the RRM1 knockdown curve to the right  













a)     Suit-2


























b)     Suit-2R c)     Suit-2R2 


























d)     Suit-2R3 e)     Suit-2R4 
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Figure 28  A cell viability assay of Suit-2G+ and Suit-2G-, Panc-1 and Panc-R comparing RRM1 
knockdown to lipofectamine only control. The absorbance on the y-axis was normalised to a value 
between zero and one to allow direct comparison of the best fit non-linear regression curve. There 
are no discernible differences in resistance in the Suit-2G lines and knockdown is likely to have not 
been completely successful or have no effect in Suit-2G+ cells. There are no obvious differences in the 
dose response curves with the Panc-1 and Panc-R cell lines  
 
gemcitabine. The resistant cell lines contrast with this in that in no case does the knockdown increase 
sensitivity, and in Suit-2R4 it is possibly increased. 
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3.5.3 The effect of RRM1 transfection on gemcitabine resistance  
 
Figure 29 demonstrates the RRM1 transfection effect after 24hrs of RRM1 cDNA treatments 
compared to the control cell line. The effect of the transfection varied between the cell lines, being 
most effective in Suit-2R3, Suit-2R4, Panc-1 and least effective in the Suit-2R, Suit-2R2 and Suit-2G 
cell lines. This may because of different levels of dependency on RRM1 in these cell lines. Figure 30 
depicts growth bar charts of each cell lines after the transfection process. There are either no changes 
observed or small decreases in viability in the cell lines Suit-2, Suit-2R2, Suit-2R3, Suit-2R4, Panc-1 
and Panc-R. There are more moderate decreases in vitality seen with the Suit-2R, Suit-2G- and Suit-




a)     Suit-2 and clonally resistant cell lines Suit-2R, Suit-2R2 and Suit-2R3 
 
Figure 29 A western blot to show the expression of the RRM1 protein at the expected molecular 
weight of 90kDa with treatment parameters RRM1 cDNA transfection compared to control of a) Suit-
2, Suit-2R, Suit-2R2, Suit-2R3 and b) Suit-2R4, Suit-2G+, Suit-2G- and Panc-1, Panc-R. There is a 
general increase in RRM1 protein level in most cell lines demonstrating successful RRM1 RNA 
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b) Suit-2R4, Suit-2G+ and Suit-2G-, Panc-1 and Panc-R 
 
 
Figure 30 A bar graph depicting the experimental control arm of the cell viability assay of all cell 
lines undergoing RRM1 transfection, as part of the drug response in figures 31 & 32. The absorbance 
result is a 96-hour snapshot of cell growth and demonstrates the variability of rates between cell lines 
and general stability with RRM1 transfection except with Suit-2R and Suit-2G+ and Suit-2G- cell lines 
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 a)      Suit-2 
 
 
       






d)   Suit-2R3          e)  Suit-2R4 
 
   
 
Figure 31  A cell viability assay of Suit-2 and clonally resistant cell lines Suit-2R, Suit-2R2, Suit-
2R3, Suit-2R4 comparing RRM1 transfection to empty plasmid transfection and a lipofectamine only 
control. The absorbance on the y-axis was normalised to a value between zero and one to allow direct 
comparison of the best fit non-linear regression curve. There are no discernible differences in 
resistance in all cell lines though the curve does move to the right with b) Suit-2R c) Suit-2R2 and e) 
Suit-2R4. In Suit-2R and Suit-2R2 the plasmid control is similarly to the left of the lipofectamine 
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Figures 31 and 32 demonstrate the cell viability experiments with drug dose response curves fitted. 
It is initially worth noting that Suit-2 cells demonstrate no variability in the curve position and 
subsequently no noticeable change in IC50. This is difficult to assess with regards to Panc-1 as the 
experiment has not produced clear results, but the RRM1 transfection curve sits between the two 
control curves, implying no change. Similarly, it is difficult to evaluate the results in Panc-R with no 
evidence of an alteration in resistance. There is no effect on resistance seen in all the clonal Suit-2 
cell lines, except Suit-2R4 which may show a shift to the right compared to the control parameters. 
Therefore, though knockdown of RRM1, at least in the parent strain (Suit-2), can increase sensitivity 
to gemcitabine, artificial overexpression makes little difference in any of the cell lines.  
 
       a)   Suit-2G+          b)  Suit-2G- 
 
   
 
       c)   Panc-1          b)  Panc-R 
 
   
 
Figure 32 A cell viability assay of Suit-2G+ and Suit-2G-, Panc-1 and Panc-R RRM1 transfection to 
empty plasmid transfection and a lipofectamine only control. The absorbance on the y-axis was 
normalised to a value between zero and one to allow direct comparison of the best fit non-linear 
regression curve. This was not possible with Suit-2G+ cell as there has been no change to resistance 
in any of the treatment parameters, hence the lack of a sigmoid curve. The Suit-2G- cell line exhibits 
a return to Suit-2 with sensitivity to gemcitabine not affected by RRM1 transfection. The Panc-1 and 
Panc-R cell line do not exhibit clear trends and the transfection process has failed to return a clear 
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In assessing the effect of RRM1 we have determined that there are cellular changes when the cell is 
exposed to gemcitabine. The experiments above are summarised in Table 7.  
 
Almost all of cell lines respond by increasing the expression of the protein in order to combat both 
cytotoxic and cytostatic effects of gemcitabine. There is a clear loss of growth when RRM1 is 
knockdown in cells and no pertinent change when it is transfected, and expression has been shown 
to increase. Only Suit-2R4 cells show that resistance can be gained through reducing RRM1 
expression, the remaining cell lines show no effect outside of growth inhibition. This compares with 
the increased sensitivity with RRM1 knockdown in the parent Suit-2 cell line. Suit-2R4 and Suit-2G+ 
are the only cell lines to show the least double stranded DNA damage at high doses of gemcitabine, 
but noticeable while Suit-2G+ also seemed resistant to gamma radiation, Suit-2R4 seemed to be as 
sensitive as the parent cell line. Suit-2R4 has a reduced level of RRM1 in its native state whereas Suit-
2G+ has a profoundly high level of RRM1 maintained by persistent gemcitabine exposure. There are 
clearly separate strategies to circumvent the cytostatic effects of gemcitabine and counteract the 
cytotoxic effects. Suit-2G+ resistance is associated with a large increase in RRM1, although knocking 
down RRM1 itself did not eliminate resistance. Whilst Suit-2R4 has resistance with a low level of 
RRM1, perhaps indicating that resistance is not associated with maintaining the nucleotide supply 
pool. The high RRM1 level concept conferring resistance is consistent in Suit-2R2, Suit-2R3 and Panc-
R who have a high expression of RRM1 compared to the parent cell lines. Suit-2R has a slow growth 
rate, low level of RRM1 and significantly less DNA damage at 250nM of gemcitabine, though it seems 
equally sensitive to gamma radiation. It is noticeable difference that Suit-2R is a slow growing cell 
compared to its parent Suit-2 and all other clonally resistant lines. There is likely to be alterations to 
the cell that affords some to overcome the gemcitabine induced replicative stress. Investigating the 
cell cycle checkpoint controls may allow further information to be gathered on how cells manage 
replicative stress and DNA damage to successfully undergo mitosis. 
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 Table 7 Summarising the experiments outcomes investigating the cytotoxic and cytostatic effects of gemcitabine on all resistant cell lines 






dsDNA damage RRM1 protein 
level 
Gemcitabine effect 
on RRM1 expression 
RRM1 knockdown 
cell viability 
RRM1 transfection      
cell viability 
Suit-2 - - Progressive increase 
with gemcitabine 
- Increases at 50nM and 
then decreases at 250nM 
Sensitivity to 
gemcitabine, reduction in 
growth 
Little change in growth rate and no 
change to sensitivity   
Suit-2R Low Low Increases but less 
than Suit-2 
Low expression Increases at 50nM and 
then decreases at 250nM 
No change to sensitivity, 
small reduction in growth 
Minimal transfection effect 
Growth rate decreases and no 
changes to sensitivity  
Suit-2R2 Low High Increases but less 
than Suit-2 
High expression Increases at 50nM and 
then decreases at 250nM 
No change to sensitivity, 
small reduction in growth 
Mild decrease to growth rate, no 
change to sensitivity 
Suit-2R3 High High Increases but less 
than Suit-2 
High expression Decreases at 50nM and 
then further at 250nM 
No change to sensitivity, 
reduction in growth 
No change to growth rate or 
sensitivity 
Suit-2R4 High High Minimal damage at 
high doses 
Low expression Increased at 50nM, 
decreases at 250nM, but 
still higher than control 
Increase in resistance, 
reduction in growth 








Increases at 50nM and 
then decreases at 250nM 
Develops sensitivity, no 
change to growth 
Minimal transfection effect, growth 
rate reduced. No change to sensitivity 
Suit-2G- Nil High Increases but less 
than Suit-2 and lower 
with positive control 
High expression Increases at 50nM and 
then decreases at 250nM 
No change to sensitivity, 
reduction in growth 
Minimal transfection effect & growth 
rate decreases. No changes to 
sensitivity 
Panc-1 - Low Progressive increase 
with gemcitabine 
- Increases at 50nM and 
then decreases at 250nM 
No change to sensitivity, 
reduction in growth  
No change to growth or sensitivity  
Panc-R High Low Increases but less 
than Suit-2 
High expression Increases at 50nM and at 
250nM 
No change to sensitivity, 
small reduction in growth 
Minimal transfection effect & no 
change to growth or sensitivity 
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3.6  The role of cell cycle checkpoint markers in the resistance of gemcitabine  
 
There are multiple checkpoint markers that have been implicated in pancreatic tumourigenesis and 
the key markers chosen for analysis are those integral to regulating  DNA replication and cell cycle 
progression. Cell cycle proteins were selected for investigation based upon literature review and 
published relationships either with gemcitabine or with ribonucleotide reductase, as discussed in the 
introduction (77-84). 
 
3.6.1 The role of p21 in resistant cell lines  
 
Figure 33 demonstrates the mean fold change in p21 RNA production. There is a marked fold 
reduction in all Suit-2R clonally resistant cells compared to the parent Suit-2 cell line: Suit-2R 0.49, 
Suit-2R2 0.50, Suit-2R3 0.41, Suit-2R4 0.37-fold change. There are no changes in expression to the 
Suit-2G+ cell line compared to Suit-2 and there is a 1.36-fold increase in p21 RNA in Panc-R cells 
compared to Panc-1. The effect on protein level, of the widespread pertinent decrease in p21 RNA in 
the Suit-2 clonally resistant cell lines, is reviewed in figure 34. All but Suit-2R3 exhibit lower level of 
p21 protein level compared to Suit-2, and the Suit-R3 line demonstrates a similar level of protein. 
The Suit-2G cell lines also exhibit a lower p21 protein level intimating an epigenetic alteration. The 
Panc-R line has similar findings at a protein level that were seen at an RNA level (figure 34). 
 
Figure 33 A bar chart to demonstrate the mean fold change of p21 RNA expression in Suit-2 and 
Panc-1 with the clonally and adaptively resistant cell lines. Each dot represents an experimental 
replicate and mean and standard errors are plotted for each cell lines. Suit-2R, Suit-2R2, Suit-2R3, 
Suit-2R4 all demonstrate at least a two-fold reduction in p21 RNA compared to Suit-2. This contrasts 
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Figure 34 A western blot to show the expression of the p21 protein at the expected molecular 
weight of 21kDa, with the housekeeping protein b-actin at the base of the blot.  The Suit-2R lines 
show reduced protein level, except Suit-2R3 which is similar to Suit-2. Suit-2G+ and Suit-2G- both 
show a reduced expression. Panc-R does exhibit a clear increase in expression 
 
p21 has a multiple cell cycle functions and increases with DNA damage to halt the G1/S transition 
but also serves as part of an anti-apoptotic cascade. The role of p21 is to halt the cell cycle and the 
reduced expression may indicate a drive to prevent cell cycle inhibition. However, if cells are unable 
to undergo mitosis because of replicative stress and a reduction in the nucleotide pool, there will 
naturally lower levels of p21. The resistance mechanisms in the clonally resistant cells may either 
be independent of p21 induction with rigid cell cycle control (Suit-2R, Suit-2R2, Suit-2R4, Suit-2G) or 
p21 may be important in protecting cells from apoptosis and progressing them through the cell 
cycle albeit it inappropriately. There is a large regulatory system and p21 plays a part of those 
processes and these cell lines utilise these in different ways. Both halting the G1/S transition and 
apoptosis are consequences of DNA damage and part of the mechanism to overcome the effects of 
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3.6.2 The role of Chk1 in resistant cell lines  
 
Figure 35 demonstrates the mean fold change in RNA expression of Chk1 in resistant cell lines. Suit-
2R, Suit-2R2 and Suit-2R3 have lower levels of Chk1 RNA at 0.72, 0.45 and 0.71-fold decreases but 
Suit-2R4 shows a two-fold increase in expression in comparison to Suit-2. Suit-2G+ cells exhibit no 
changes compared to the parent line. Panc-R has a two-fold reduction in Chk1 RNA expression. 
With respect to the impact on protein levels, figure 36 shows potential increases in Chk1 protein 
level in the Suit-2R2, Suit-2R4, Panc-R and most markedly in the Suit-2R3 cell lines. Suit-2R4 exhibits 
increased RNA expression but this does not translate to protein levels implying there is a post-
translational modification to prevent the cell from arresting. The actin levels of Suit-2 are more 
marked compared to the other cell lines, which may lead to the conclusion that the Suit-2 G- and 
Suit-2G+ show no changes in expression, similar to the RNA fold changes. There certainly a reduced 
expression of Chk1 in the Suit-2R line.  
 
Chk1 has a role at every cell phase and mediates DNA repair mechanisms. The DDR pathway is 
activated by the ATM and ATR proteins and given the likely gemcitabine induced DSB, the Chk1 
marker is likely to be integral to affording time for repair by way of cell cycle arrest or by preventing 
arrest and accepting a degree of damage in order to pursue cell growth. The variations seen in 
checkpoint markers so far imply different mechanisms to resistance. The Suit-2G line demonstrate 
no change implying continued cell growth whereas as Suit-2R4 has dampened down the genetic 
response in order to prevent arrest. Suit-2R has low level Chk1 and slow growth which may relate 
to a generalised cell cycle slow down, not specifically to Chk1 phase progression. These findings 
have to be combined with other markers and reviewed specifically to each resistant cell line, as is 





Figure 35 A bar chart to demonstrate the mean fold change of Chk1 RNA expression in Suit-2 and 
Panc-1 with the clonally and adaptively resistant cell lines. Each dot represents an experimental 
replicate and mean and standard errors are plotted for each cell lines. The clonally resistant cell lines, 
Suit-2R, Suit-2R2, Suit-2R3 and Panc-R all exhibit reductions in Chk1 RNA expression. There are no 
obvious changes in the Suit-2G+ lines and Suit-2R4 is the only cell line that show an increase in RNA 
expression compared to the parent cell line  
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Figure 36 A western blot to show the expression of the Chk1 protein at the expected molecular 
weight of 56kDa, with the housekeeping protein b-actin at the base of the blot. There is a higher level 
of actin expression in the Suit-2 line which does affect the interpretation of the blot, but it is clear that 
Suit-2R3 and Panc-R are higher in protein levels. This also may lead to the conclusion that Suit-2R2 
and Suit-2R4 have increased expression or a the very least similar levels to the parent Suit-2 line. The 
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3.6.3 The role of CyclinD1 in resistant cell lines 
 
The presence of the G870A polymorphism will have an effect on the protein levels of Cyclin D1a and 
D1b and the presence of the minor and major allele were investigated by SNP genotyping shown in 
Figure 37. Part B demonstrates the immortalised cell lines Suit-2, Panc-1 and BxPC3 with homozygous 
minor, heterozygous and homozygous major alleles respectively. Part A confirms these findings with 
the Suit-2, Suit-2R, Suit-2R2, Panc-1 and Panc-R cell lines used in this thesis. Cyclin D1a and D1b were 
investigated separately to elicit the predominance of the variant in the homozygous minor allele of 
Suit-2. Cyclin D1 RNA analysis was not carried out for the Panc-1 cell line.   
 
  
Figure 37  A: SNP genotyping of G870 polymorphism in Suit-2, Suit-2R and Suit-2R2 cells (all are 
blue dots (triplicate), homozygous minor allele), Panc-1 and Panc-R (all orange dots (triplicate), 
homozygous major allele) with sterile water controls (black dots (triplicate). B: SNP genotyping of 
Suit-2 (blue (triplicate, two different passages of Suit-2), homozygous minor allele), BxPC3 (green dots 
(triplicate), heterozygous) and Panc-1 (orange dots (triplicate), homozygous major allele). 
 
Figure 38 demonstrates the mean fold change in RNA expression of Cyclin D1a in the Suit-2 cell lines. 
There is a cell line wide increase in mean RNA fold change: Suit-2R 5.13, Suit-2R2 7.95, Suit-2R3 1.83 
and Suit-2R4 1.479. It would be pertinent to compare this to the Cyclin D1b RNA expression as seen 
in figure 39.  There are similar patterns in that Suit-2R and Suit-2R2 both exhibit significantly larger 
mean fold change increases of 17.02 and 17.50 respectively. Suit-2R3 and Suit-2R4 exhibit a smaller 
increase in expression compared to the parent; 7.37- and 6.41-fold changes respectively. From an 
RNA expression perspective there are increases in Cyclin D1a and D1b, predominately in the spliced 
variant form highlighting its importance to the cell cycle.  Figure 40 investigates the protein levels of 
Cyclin D1a and Cyclin D1b in all resistant cell lines and is the same blot at two exposures to enable 
optimal comparison of both bands.  
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Figure 38 Bar charts to demonstrate the mean fold change of CCND1a RNA expression in a) Suit-
2 and the clonally resistant cell lines. Each dot represents an experimental replicate and mean and 
standard errors are plotted for each cell lines. Though there is widescale increase in mean RNA 
expression, there are large increases with respect to Suit-2R and Suit-2R2.   
 
 
Figure 39 Bar charts to demonstrate the mean fold change of CCND1b RNA expression in a) Suit-
2 and the clonally resistant cell lines. Each dot represents an experimental replicate and mean and 
standard errors are plotted for each cell lines. There are significant increases in RNA expression across 
all lines. Similar to figure 33, there are widescale increases in mean RNA expression, largest in the 
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a)      
 
b)      
 
Figure 40a&b  A single western blot at two exposures to contrast the expression of the Cyclin 
D1a and D1b at the expected molecular weights of 37kDa with D1b being lighter, with the 
housekeeping protein b-actin at the base of the blot. The Suit-2R and Suit-2R2 lines exhibits decreases 
in both variants, more so in D1a, whereas Suit-2R3 and Suit-2R4 both have increased expression, more 
so in D1a. Both Suit-G lines show a large increase in Cyclin D1a and smaller increases in Cyclin D1b. 
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There are two trends that exist in the Suit-2 clonally resistant cell lines which correlate with the RNA 
expression. Suit-2R and Suit-2R2 both exhibit increases in D1a and D1b RNA expression which does 
not translate to increased protein levels. Indeed, both D1a and D1b are reduced compared to the 
parent Suit-2 line. Cyclin D1b had more prominent protein levels compared to D1a, in line with the 
higher RNA fold change in this spliced variant. The second trend exists with Suit-2R3 and Suit-2R4 
where there is less substantial increase in RNA expression, with Cyclin D1b demonstrating a higher 
fold change. In these cell lines, the Cyclin D1a D1b protein levels are higher compared to the parent. 
Despite the fact that the D1b RNA expression being higher it is the protein level of D1a that shows 
the greatest increase. The Suit-2G+ and Suit-2G- cell lines both exhibit a significant increase in Cyclin 
D1a compared to Suit-2 cells with no obvious difference with D1b.  
 
There is a clear different in Cyclin D1 in these cell lines, and the impact of the splice variant is likely 
to play an important role with the clonally resistant line, especially considering its relative 
redundancy compared to D1a in the Suit-2G cell lines.  
 
Panc-1 cells produce no Cyclin D1a and only express D1b which is related to its major allele G 
polymorphism. There is little difference with respect to the Panc-R Cyclin D1b expression suggesting 
that Cyclin D1 may not play a prominent role in the resistance to gemcitabine in this cell line.  
Given the marked findings in Cyclin D1a and D1b expression, there is likely to be an important role in 
the mechanism of gemcitabine which may be related to growth rates and cell cycle regulation in Suit-
2. This is probably related to the homozygous minor allele in this cell line.  
 
3.6.4 The effect of Cyclin D1 siRNA interference on gemcitabine resistance 
 
The accumulation of Cyclin D1 is essential for transition into S phase and knocking down this protein 
should induce cell cycle arrest and may affect how resistant cells are to gemcitabine. Figure 41 shows 
a western blot of a Cyclin D1 knockdown compared to controls and figure 42 demonstrates a 96hr 
snapshot into cell growth. It depicts that Suit-2R has almost no change in growth rates compared to 
the parent Suit-2 cell line that has a 59% drop compared to control. Cell growth drops by 50% in the 
Suit-2R2, Suit-2R4 and Suit-2G cell lines and by up to 25% in Suit-2R3, Panc-1 and Panc-R cell lines. 
Though it is difficult to ascertain the exact cause of this drop, the fact that Suit-2 sees no change may 
allow the conclusion it is related to the lack of Cyclin D1 and not just from the lipofectamine 
experimental conditions of the control. 
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Figure 41 A western blot to show the expression of the cyclin D1 protein in Suit-2 cells at the 
expected molecular weight of 37kDa with treatment parameters of lipofectamine only (LF), Off Target 
knockdown (OT) and RISC-Free (RF) knockdown. This blot demonstrates successful knockdown of 
cyclin D1 after 24 and 48 hours treatment of cyclin D1 siRNA, in Suit-2, Suit-2R and Suit-2R2 cell lines 
 
Figures 43 and 44 depict cell viability curves for the Cyclin D1 interference assays and it is worth 
commenting from the outset that actual dose response curves proved difficult in many cases due to 
the detrimental effects of the knockdown. With the parent strain, knockdown of Cyclin D1 results in 
an increase in sensitivity to gemcitabine at lower doses. Whereas there is no impact to Suit-2R, and 
in Suit-2R2 and Suit-2R3 may even increase resistance. Only in Suit-2R4 is there a possibility of 
increased sensitivity. From figure 42, it can be seen that the slowing of growth is not additive or 
synergistic with the impact of gemcitabine, suggesting that the resistance mechanism in Suit-2R and 
possibly Suit-2R2 and Suit-2R3 are associated with a resistance to cell growth inhibition by 
gemcitabine, and may even benefit. This contrasts with Suit-2R4 where the inhibition of cell growth 
does not seem to protect from gemcitabine, and may enhance its effect.  Panc-1 and Panc-R cell lines 
do demonstrate some general reduction in growth with the impact on gemcitabine resistance is 
difficult to evaluate as there doesn’t seem to be a difference between resistant and parent cell line.  
The Suit-2G cell lines show that the knockdown and lipofectamine treatment required prolonged 
culture time and there is clearly a transition from G+ to G-. This experiment shows that the 
interference process brings a sensitivity to gemcitabine independent of the knockdown. This effect 
is also seen in figure 28.  




Figure 42 A bar graph depicting the experimental control arm of the cell viability assay of all cell 
lines undergoing RRM1 transfection, as part of the drug response in figures 37 & 38. The absorbance 
result is a 96-hour snapshot of cell growth and demonstrates the general decrease in rates across all 
cell lines except Suit-2R. There are lesser reductions in growth with respect to Suit-2R3, Panc-1 and 
Panc-R but even the more significantly affected cell lines are less that the 59% reduction seen in the 
parent Suit-2 cell line.    
 
Half of these curves fail to produce satisfactory drug responses and conclusions are difficult to elicit. 
Some cell lines with low Cyclin D1 demonstrate no effects to growth or potentially some changes to 
resistance. The role of Cyclin D1 cell cycle regulation to gemcitabine resistance is not clear.  
The three cell cycle regulatory markers analysed here are part of a complex cascade that results in 
either progression through the cell cycle, an arrest to afford repair mechanisms or driving apoptosis 
of the cell. There appears to be in this respect at least two resistance patterns exemplified by Suit-2R 
and Suit-2R4, with the former dependent upon or at least not adversely affected by cell cycle 
inhibition. The contrasting mechanism of Suit-2R4 is antagonised by cell cycle inhibition and is not 
augmented by this process. The genotype (derived from the parent cell line) would promote the 
expression of cyclin D1b. Table 8 summarises the checkpoint marker observations in all resistant cell 
lines. In Suit-2R. In Suit-2R the cyclin D1b expression is evident but the total level of cyclin D1 is 
reduced, potentially as part of the resistance mechanism. In contrast in Suit-2R4 the preference for 
D1b is lost despite the cell line continuing to have the minor allele, and at the RNA level the cell line 
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a)      Suit-2 
 
 
       
 b)   Suit-2R          c)  Suit-2R2 
 
 
   
 
 
d)   Suit-2R3          e)  Suit-2R4 
 
   
 
Figure 43  A cell viability assay of Suit-2 and clonally resistant cell lines Suit-2R, Suit-2R2, Suit-
2R3, Suit-2R4 comparing Cyclin D1 knockdown to lipofectamine only control. The absorbance on the 
y-axis was normalised to a value between zero and one to allow direct comparison of the best fit 
non-linear regression curve. Suit-2 cells have such a deleterious effect on growth that a drug 
response curve is not possible, whereas Suit-2R and Suit-2R2 do converge to demonstrate no change 
to resistance and a possible increase, respectively. Suit-2R3 and Suit-2R4 show a gradual decrease in 
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  a)   Suit-2G+          b)  Suit-2G- 
 
   
 
       c)   Panc-1          b)  Panc-R 
 
    
 
Figure 44 A cell viability assay of Suit-2G+, Suit-2G-, Panc-1 and Panc-R comparing Cyclin D1 
knockdown to lipofectamine only control. The absorbance on the y-axis was normalised to a value 
between zero and one to allow direct comparison of the best fit non-linear regression curve. Though 
lipofectamine controls do cause some gemcitabine sensitivity to Suit-2G+ cells, there is a shift in the 
drug dose response curve to the right indicating increasing resistance. This is not apparent in the Suit-
2G- cell line where there may be a small increase to sensitivity. Similar to Suit-2R3 and Suit-2R4 in 
figure 37, the Panc-1 and Panc-R cell lines demonstrate a general decline in viability at higher doses 
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Table 8 Summarising the differences in RNA and protein level to the checkpoint markers p21, 
Chk1, CyclinD1 in all experimental cell lines. 
 
  





G1/S & G2/M marker 
CyclinD1 
G1/S checkpoint marker 
Suit-2 - - Expressed D1b protein more so than D1a 
Suit-2R Reduced RNA and 
protein level 
Reduced RNA and 
protein level 
Increase RNA levels, 
D1b expression > D1a 
Protein levels reduced 
D1b more prominent 




protein level to parent 
Increase RNA levels 
D1b expression > D1a 
D1a absent, D1b level lower than control 
Suit-2R3 Low RNA production, 
similar protein level 
to parent 
Minimal change in RNA 
expression and increase 
in protein level 
compared to parent 
Increase RNA levels  
D1b expression > D1a 
D1a protein increased compared to 
control, lower level of D1b expression 
Suit-2R4 Reduced RNA and 
protein level 
Increase RNA expression, 
mild increase in protein 
level compared to 
parent 
Increase RNA levels,  
D1b expression > D1a 
D1a protein increased compared to 
control, lower level of D1b expression 
Suit-2G+ Similar RNA 
expression to parent, 
protein level reduced  
No change in RNA or 
protein level 
Large increase in D1a, minimal change to 
D1b protein level  
Suit-2G- Protein level reduced RNA not performed. No 
change in protein levels 
Large increase in D1a, minimal change to 
D1b protein level 
Panc-1 - - Only expresses D1b 
Panc-R Increased RNA and 
protein level 
Reduction in RNA 
production and mild 
increase in protein 
Only expresses D1b at a lower level to 
parent Panc-1  
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There are certain trends that can be described from the observations above: 
 
1. p21 is poorly expressed in all Suit-2 resistant cell lines compared to the parent. Given its 
importance to overcoming replicative stress, this may present a cells willingness to accept 
DNA aberrations secondary to gemcitabine. Or there is a lack of active cell cycle division 
independent of p21. 
 
2. Suit-2R and Suit-2R2 exhibit poor expression of all three markers when compared to Suit-2R3 
and Suit-2R4. Suggesting these two lines may have a shared resistance mechanism dependent 
on a breakdown of checkpoint regulation. Indicating that these cells do not need these 
checkpoints because the cell is dividing poorly or can survive the damages that require a 
checkpoint. For Suit-2R3 and Suit-2R4 induction of checkpoints may be occurring normally, 
indicating they are actively attempting to divide.   
 
3. The Suit-2G+ cell line is dependent on Cyclin D1a to maintain cellular division, especially since 
p21 and Chk1 are not significantly raised which is expected because dsDNA damage is not 
increased. Indicating the DDR response is functioning normally in this cell line.  
 
4. Although clonally resistant cell lines over express Cyclin D1a and D1b at an RNA level, this is 
mitigated at a protein level in all cases. Either through downregulating both D1a and D1b (Suit-
2R) or by targeted reduction in D1b relative to D1b (Suit-24). Those cell lines with minimal 
dsDNA damage from gemcitabine treatment, have high levels of D1a (Suit-2G+ and Suit-2R4) 
whereas those cells with higher dsDNA damage have reduced cyclin D1a, maintaining a 
preference for D1b. This switch maybe protective from the Cyclin D1a induced cell cycle arrest, 
whereas the cell lines that undergo DNA repair efficiently may depend on the Cyclin D1a 
increase as a stimulus for this process. The siRNA interference experiment shows that Suit-2R 
and Suit-2R2 may have a protective effect from having low levels of Cyclin D1a.  
 
Gemcitabine resistance is reliant on being able to overcome the effects of replicative stress caused 
by direct damage to DNA or directly by nucleotide starvation. Gamma irradiation causes DNA 
damage in all the resistant cell lines with Suit-2G+ having reduced damage compared to parent, 
whereas all the clonally resistant cell lines have increased damage (most prominent in Suit-2R3). 
The resistance mechanisms in the clonal cell lines is not the result of prevention/repair of double 
strand breaks, which is unlikely to be the case with Suit-2G+ cells. The adaptively resistant cells 
have a massive increase in RRM1 which would prevent nucleotide starvation and allow cell division 
with consequent risk of double strand breaks. Resistance to these breaks is a logical strategy to 
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overcome the effect of gemcitabine. Suit-2R and Suit-2R4 has a low level of RRM1 that would be 
expected to lead to nucleotide starvation which would lead to a reduction in cell division causing 
replicative stress. The absence of checkpoint markers in Suit-2R indicated that the replicative stress 
is not being overcome by these regulatory mechanisms, and may indicate that the cell has adapted 
to cope with continuing levels of stress. In Suit-2R4 these cells are inducing checkpoint markers 
suggesting a different resistance mechanism in overcoming replicative stress.  
 
The checkpoint markers p21 and Chk1 are responsible for DNA damage response and regulate 
transition into the progressive phases. The function of Cyclin D1 is also important here because the 
G1/S transition specifically depends upon Cyclin D1 induced kinases. Broadly speaking an 
accumulation of Cyclin D1 pushes the cell cycle into S phase. If we review the cells that have higher 
Cyclin D1a levels then we can assess those cell that have DNA damage or mitigated DNA damage 
that push through the G1/S transition, and those that do not. The cells that do not pass this 
transition enter an arrest phase to allow further DNA repair and await degradation of gemcitabine. 
This is where Cyclin D1b can play a role as it is less effective as D1a at the G1/S transition, as it is a 
poor activator of CDKs. 
 
Ultimately final analysis of these markers and collating the cytostatic and cytotoxic analyses required 
cell cycle analysis, which is the focus of the following section.  
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3.7  The cell cycle effects of gemcitabine resistance mechanisms  
 
In order to further explore the experiments performed on how ribonucleotide supply, DNA damage 
and cell cycle checkpoint controls influence gemcitabine resistance, cell cycle analysis is essential. A 
cell sorting analysis was performed using FACS with the experimental parameters of mean IC50 
gemcitabine dose and high dose, similar to above experiments. There were two sets of FACS 
experiments performed for each cell line with the second set including the supernatant of the culture 
medium and the cells adherent to the plate surface. This provides a wider perspective on the cell 
cycle and allows comparison of the cells that detach through mitosis or morbidity or death. There 
were attempts made at isolating the supernatant separately but this proved difficult as the FACS 
preparation process causes a degree of substrate loss. Figure 45 shows a representative analysis of a 
FACS experiment. 
     a) Cell height vs cell area                b) Frequency histogram            c) Gated frequency histogram  
 









Figure 45  A representative cell sorting analysis of Suit-2 cells using the BL2 blue laser to detect PI 
staining: a) Scatter plot of cell height vs area, b) Frequency histogram of all data points, c) Frequency 
histogram encompassing gating as demonstrated in a), d) Frequency histogram demonstrating cell cycle 
population using normal distribution modelling, percentages used for following figures  
    G1         S         G2 
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Figure 46 depicts FACS analysis of all the Suit-2 clonally resistant cell lines and has multiple findings. It is 
worth noting that Suit-2 cells demonstrate the S phase replication stress bulge (55% at 250nM of 
gemcitabine) where the cytotoxic and cytostatic effects of gemcitabine prevent successful DNA replication 
and repair. This leads few cells to enter G2 and subsequently the supernatant contains many cells in G1 
and S (91.5%). Suit-2R and Suit-2R2 have a predominant G1 phase at all doses of gemcitabine with no 
widening of S phase (53.2 and 55% at 250nM respectively). In the attached cells the S-phase, with or 
without gemcitabine, is relatively small but is greater for all forms of treatments when you include the 
cells unattached. This suggests that a larger proportion of the dying cells are in S-phase. Consistent with 
this, there is an increase when you included the supernatant as you increase the dose of gemcitabine. 
There is potentially a cell cycle arrest to afford DNA repair which explains why the supernatant contains 
more G1 and S phase cells in Suit-2R (total 97.7% at 250nM gemcitabine). With regards to the supernatant, 
Suit-2R2 appears to drives cells into G2 at the lower dose of gemcitabine (27.6%) but at the higher dose 
succumb to S phase non-viability (68.8%). The attached Suit-2R3 cells display a S-phase bulge as the dose 
of gemcitabine increases (43.3% at 250nM gemcitabine) but when including the supernatant is there is an 
obvious increase in G2 (14.5% in the control to 33.4% at 250 nM gemcitabine). This suggests cells are 
pushing through to G2 and into mitosis but struggling to complete cell division. Suit-2R4 cells have the 
highest proportion of cells in G2 as the dose of gemcitabine increases but, including the supernatant, 
there are non-viable cells in G1 and S phases. There is a process that sees cells through to G2 successfully 
but there is more death at the preceding phases. Looking at the distinct resistance mechanisms ascribed 
Suit-2R and Suit-2R4, in the former cells are remaining viable and arrested in G1, attempts to go beyond 
G1 result in unattached cells. In Suit-2R4 cell lines, they are able to avoid arrest and enter G2 and the 
unattached cells appear to accumulate in G1. Remaining in G1 is a survival strategy for Suit-2R but in Suit-
2R4 where cell division is maintained, if it fails to progress cells dies in G1 and S. Suit-2R2 seems similar to 
Suit-2R but Suit-2R3 looks distinct from both Suit-2R and Suit-2R4. In these cells there is replicative stress, 
as shown by the S-phase bulge, but cells do not appear to be dying as a result. The cells that die appear 
to have entered G2, perhaps due to mitotic catastrophe. Thus, revealing a potential third resistance 
mechanism to gemcitabine.  
 
With respect to the Suit-2G cell lines, figure 47 depicts that Suit-2G+ appears to drive cells into G2 with 
higher doses of gemcitabine with 50.1% of cells in that phase. There is no evidence of replicative stress, 
and the cells including the supernatant show a diffuse loss cells at all phases, with approximately 36% in 
G1, 25.5% in S and 38.5% in G2. With Suit-2G- the attached cells show no impact of gemcitabine, without 
an S phase widening or a G2 increase indicating some cells remain resistant. 
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Figure 46  Horizontal bar graphs depicting cell sorting analysis experiments as cell cycle percentages 
of a) Suit-2 b) Suit-2R c) Suit-2R2 d) Suit-2R3 e) Suit-2R4 cell lines. On the left were trypsinised cells only and 
on the right are cells that included the supernatant. Suit-2R & Suit-2R2 cells exhibit no S phase bulge as seen 
in Suit-2 and Suit-2R3 and 53.2% and 55% of cells remain in G1 respectively. There are cells that have 
sloughed off in the supernatant at higher doses of gemcitabine and few cells enter into G2 (10.5% and 2.3% 
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or not and this is seen as the cells that in the supernatant are predominately G2. Suit-2R4 cell lines have the 
lowest proportion of cells in S phase and the highest in G2 at 250nM of gemcitabine indicating that cells are 
entered into G2 rapidly, and the deatched cells succumb to death in earlier phases. 
  
Figure 47 Horizontal bar graphs depicting cell sorting analysis experiments as cell cycle 
percentages of a) Suit-2 b) Suit-2G+ and c) Suit-2G-. On the left were trypsinised cells only and on the 
right are cells that included the supernatant. Neither Suit-2G cell exhibited the S phase bulge, and 
Suit-2G+ demonstrates a progression through the cell cycle with higher proportions in S and G2 at 
higher doses of gemcitabine. There is a consistency in the supernatant at all cell lines, with no effect 
with gemcitabine. Suit-2G- cells exhibit similar stability with almost equal cell cycles proportions but 
when including detached cells, there is S-phase death. These cells have to to return to sensitivity.  
 
When including the supernatant, there is a significant number of cells that have lost this resistance and 
are dying as typical in S-phase (66.2%) with few in G2 phase (3.4%). Suit-2G- has not completed its journey 
to sensitivity and there are heterogenous populations of cells that are resistant or undergo replicative 
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Figure 48 Horizontal bar graphs depicting cell sorting analysis experiments as cell cycle 
percentages of a) Panc-1 and b) Panc-R. On the left were cultured cells with culture medium discarded 
and on the right are cells that included the supernatant. The Panc-1 cell lines demonstrates the 
widening S phase as with Suit-2 and sees cells sloughing off in predominately S phase, as expected 
with the effects of gemcitabine though prefers to progress to G2 with 50.5% at control. There is 
remarkable stability with Panc-R cells at all parameters at the base of the plate, though cells fail to 
survive in S-phase when combining the supernatant (27.7% vs 48.8%) . There is a drive to leave S-
phase and push into G2, despite the risk of death 
 
Figure 48 demonstrates the Panc-1 cell lines which does exhibit the S phase bulge from 1.6% to 32.6%, 
control to 250nM of gemcitabine in the parent line. Even in the absence of gemcitabine, in contrast to 
Suit-2, there are very few cells in S-phase. Most that are in this phase have detached from the plate. When 
combining the supernatant there are high loses at G1 and S phases with a total proportion of 100% and 
93.4% at 50nM and 250 nM of gemcitabine respectively. This implies that cells are unhappy in S-phase 
and sensitive to replicative stress. Panc-R maintains a stable cell cycle throughout treatment of 
gemcitabine with approximately 44% in G1, 28% in S phase and 28% in G2, with cells attached to the plate. 
This implies an ability to survive in S-phase compared to the sensitive parent. Combining the supernatant, 
at 50nM of gemcitabine there begins an increase in G1 and S phase non-viability with 35.8% and 37.5% 
respectively and then at 250nM more cells slough off in S phase (48.8%). Although there is stability in the 
attached cells, there are a lot of cells trapped in S phase as the dose of gemcitabine increases. Panc-R 
tolerates replicative stress like Suit-2R4 in comparison to its parent strain, but there is evidence that Panc-
1 is more resistant to gemcitabine that Suit-2. 
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The resistance mechanisms can be loosely divided into the ability to tolerate replicative stress and an 
ability to avoid replicative stress. Suit-2R is an example of avoiding replicative stress with an accumulation 
of cells in G1. Suit-2R4 is archetypal of a cell line that tolerates replicate stress with large proportions of 
cells in S phase progressing to G2. Suit-2R3 is another example of a cell line tolerating replicative stress, 
but in this case has higher non-viability as it enters G2/M. It completes DNA replication but suffers the 
consequence of replicative stress as the cell tries to divide. There are fewer cells in G2 overall when 
considering the supernatant suggesting that cell death occurs earlier in the cell cycle because of 
gemcitabine induced stress replication.  
 
There are clearly significant differences in the behaviour of these cell lines at a cell cycle perspective 
and a summary of all experiments performed in all cells lines is show in Table 9.  
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4.  Discussion 
 
Chemotherapy treatment of pancreatic cancer has only recently progressed from a single drug 
regimen to either coupled or multiple combination therapies with gemcitabine or 5-fluorouracil (5-
FU) as their base. These traditional chemotherapy agents remain the foundation of treatment in 
pancreatic cancer. Clinical trials have proven the increased effectiveness and highlighted the 
particular need for biomarker detection. The 5-FU based four drug FOLFIRINOX regime is a broad-
spectrum solution that brings with it a wide spectrum of toxicity complications. For this reason, the 
elderly and co-morbid populations are still receiving single agent regimens of gemcitabine  or dual 
combination coupled with capecitabine. There have been high reported rates of gemcitabine 
resistance and given the increase in chemotherapeutic options, a more tailored approach would 
allow patients to receive the most efficacious therapy and avoid the most deleterious to their health 
(5, 27). Investigating the resistance mechanisms of the tumour could allow a personalised 
chemotherapy approach by identifying which patients are likely to develop resistance and possibly 
identify methods to overcome this. In this thesis, evidence has been presented that there is not just 
one resistance pathway, and that resistance can be achieved through very different strategies. All of 
which need to be properly understood in order to identify biomarkers appropriately. For example, 
high and low levels of ribonucleotide reductase can be selected for, to give resistance in different 
individuals.  
 
4.1  Resistance generation  
 
In researching the methodologies of developing gemcitabine resistant pancreatic cancer cells, the 
relatability to a clinical chemotherapy drug regimen was a pertinent consideration. The exposure of 
established pancreatic cancer cells to progressively increasing doses of gemcitabine does not relate 
to clinical practice. Patients receive one dose of gemcitabine once a week for two to three weeks and 
then further doses for a tailored number of cycle regimens, or until the patient is unable to tolerate 
the side-effects any longer. Therefore, the exposure of a pancreatic tumour to a chemotherapy drug 
is not at a consistent level and not for a constant period of time. This is a pulsed regimen and any in 
vitro experiments need to reflect that process for conclusions to be translatable.  
 
Panc-1 and Suit-2 immortalised pancreatic cancer cell lines are sensitive to gemcitabine, though the 
former has a higher degree of resistance, as shown by an IC50 of 15.4nM compared to 10.1nM. In 
order to develop resistance, a process is required to select populations of cells that are resistant to 
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gemcitabine. Two methods were employed; clonal selection or increasing dose exposure as adaptive 
strategies to resistance. The single cells that survive exposure to gemcitabine develop mechanisms 
to enable DNA replications and mitosis, or have innate characteristics that allow cell growth. When 
the clonally isolated resistant cell lines were developed, strategies to pulse gemcitabine on a more 
frequent basis resulted in widespread death. This was because cells were unable to compensate for 
the effects of the drug or degrade it quickly enough. Surviving clonal islands only consisted of a few 
cells on a 96-well plate. Whereas adding further gemcitabine to a T75 flask of Suit-2 cells afforded 
many cells of varying innate functionality to manage the cytotoxic and cytostatic effects. This self-
selects a heterogenous population in comparison to those cells that are clonally isolated. Once 
gemcitabine is degraded by a sub-population of cells in a heterogenous population, other cells will 
avoid replicative stress because nucleotide levels will be maintained. Once gemcitabine is removed 
from culture media then the non-resistant cells are able to grow freely and the population will 
become sensitive. Whereas the single isolated cell undergoes mitosis as the only gemcitabine 
surviving clone, giving a population of resistant cells. Clearly there are implications to the 
development of both resistance strategies that will impact on their clinical significance.  These will 
be discussed after the resistance mechanisms have been considered.  
 
4.2 Fundamentals of gemcitabine resistance  
 
The fundamentals of gemcitabine toxicity stem from the induction of stress to the DNA replicative 
phase, directly through incorporation into DNA and indirectly by obstructing the production of 
nucleotides. Replicative stress results from an inability for a cell to undergo DNA synthesis in the 
absence of a process to stop replication. DNA damage which induces cell cycle arrest therefore does 
not cause replicative stress (DNA damage that does not cause cell cycle arrest will cause replicative 
stress by definition). In its very nature, it induces cell cycle death by preventing division and 
interfering with normal cell division processes. In order for a pancreatic cancer cell to survive this 
insult, it has to either prevent entry of gemcitabine or compensate/negate its effects. In order for a 
cell to compensate for the effects of gemcitabine, survival will involve regulation of cell cycle 
progression. Either by arresting the cell cycle to allow DNA repair processes or to pushing through 
replication at the cost of damaged DNA which somehow the cell manages to survive. The premise 
that resistance can either result from avoiding DNA damage or by tolerating DNA damage underlies 
this thesis. The experimental findings of DNA damage, ribonucleotide reductase alterations and 
adjusted cell cycle checkpoint markers all combine to explain how cell cycle regulation may increase 
the chance of cell survival.  
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4.2.1 Adaptive resistance  
 
The Suit-2G+ cell line appears to have a clear resistance process with the overwhelming increase in 
RRM1 acting as its primary focus. The increased production of ribonucleotide reductase could 
counter the toxic effects of gemcitabine allowing the dilution of dFdCDP by unmodified 
deoxynucleotides. There is no increase in RRM2 or p53R2 explained by the fact that RRM1 is bound 
by gemcitabine. The production of a functional RR complex may not only obviate the cytostatic effect 
of gemcitabine but allow the increase of the foundation blocks for DNA replication. We only see 
double stranded DNA damage at higher concentrations of gemcitabine and even then, it is still 
significantly less than with the Suit-2 cell lines. This may be explained by a greater proportion of RRM1 
being free of dFdCDP giving a greater production of the non-cytotoxic dCTP (which will compete with 
the fluorinated nucleotide reducing DNA damage). There is some confirmation of this process by the 
fact that RRM1 increases when Suit-2G+ cell lines are treated with gemcitabine as seen in figure 24b. 
However, the RRM1 siRNA interference process does not seem to affect resistance, indicating that 
once resistance has been established the requirement for high levels of RRM1 may no longer 
absolute. In Suit-2G+ cells both p21 and Chk1 are low in expression indicating that DNA damage is 
not inducing cell cycle arrest, but may be causing replicative stress. Hence why Cyclin D1a is 
accumulated in these cells. The cell functions with high efficiency which is explained by the FACS 
analysis, where the only changes seen are an increase through to G2 and consistency with the 
supernatant. Quite simply gemcitabine stimulates this cell into rapid and effective growth which is 
also the reason why an IC50 cannot be produced, a growth reduction in 50% is not achieved even at 
the highest concentrations employed. The initial resistance development process selected cells that 
were able to produce high amounts of RRM1 and they continued to select and divide at higher doses 
of gemcitabine.  
 
Further support of the Suit-2G+ theory are the experimental findings of Suit-2G-. The removal of a 
gemcitabine stimulus returned these cells to a normal sensitivity with an IC50 of 12nM but the effects 
of once being Suit-2G+ cells still linger. There is still a high level of RRM1 protein and significantly 
increased DNA damage, as seen in Suit-2 cells. There may not be enough of an increase in RRM1 
expression to compensate for the cytotoxic damage caused by gemcitabine, alternatively other 
changes necessary for resistance found in Suit-2G+ may have been lost. The cell cycle checkpoint 
markers still remain similar to the Suit-2G+ cell line with low levels of p21 and Chk1 and high 
CyclinD1a expression. The cells have adapted to a rapidly transitioning cell cycle but are succumbing 
to stress replication and cell death in S phase in the presence of gemcitabine. This is seen in the cell 
cycle analysis where cells are progressing into S/G2 but are non-viable, as they detach into the 
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supernatant. In fact, just reviewing the cells adherent to the plate, there is almost no effect of 
gemcitabine. These cells have lost resistance but the resistance mechanisms in place still apply to the 
sub-population that managed to survive in the presence of gemcitabine. When CyclinD1 is knocked 
out, the cell cycle is inhibited  and the sensitivity to gemcitabine increases. Presumably because most 
cells are unable to drive into the mitotic process and those that are, die during in S phase. The Suit-
2G cell lines require gemcitabine exposure to maintain resistance to it and there is a threshold when 
the increase in RRM1 expression is sufficient to overcome the bimodal toxicity of gemcitabine.  
 
4.2.2 Clonal resistance 
 
The clonal isolation cell lines remain resistant without gemcitabine, albeit at significantly lower levels 
compared to Suit-G+. The lowest IC50s belong to Suit-2R and Suit-2R2 (24.3nM and 22.8nM 
respectively) and the highest to Suit-2R3, Suit-2R4 and Panc-R (86.7nM, 52.7nM and 61.7nM 
respectively). The difference between the IC50s in Suit-2R/Suit-2R2 and suit-2R3/Suit-2R4 already 
indicated potential differences in resistance mechanisms. The lower IC50s in comparison to Suit-2G+ 
may be explained in their culturing maintenance. With respect to Suit-2G+ cells, a position has been 
reached where gemcitabine is totally destroyed or prevented from entering the cells at all. This state 
is maintained by the presence of gemcitabine. This is analogous to an individual who maintains 
lactose tolerance while they are exposed to dairy products but when dairy is removed, an individual 
may gradually over time become lactose intolerant. In the clonal cells this is more analogous to 
individuals who are lactose intolerant due to inherited mutations and in order to become tolerant 
would require further mutation. These are cell lines that grew from a mutated single cell that was 
able to multiply in cell culture infused with gemcitabine. There was no further cell selection except 
at that initial single cell level. A clonal isolation cell line grown without gemcitabine in conjunction 
with clonal cells grown with increasing doses, would have provided a more relevant control that the 
parent Suit-2 cell line, this was not carried out at the beginning of the resistance generation process. 
 
It must be considered that the delivery of the active gemcitabine metabolite, into the cell may be 
altered, and though there were no obvious changes to CDA or DCK discovered, the possibility of 
hENT1 expression alterations cannot be ruled out. However, in this thesis, it has demonstrated that 
regardless of any change to influx there are changes in the level of gemcitabine target in all the 
resistance cell lines. Looking further into the metabolism of gemcitabine and given the prominent 
role of RRM1 in the Suit-2G+ cell line, it is a pertinent starting point to try and describe the delicate 
balance between DNA replicative stress and cell cycle progression.  
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The five clonally resistant cell lines can also be divided into two groups based upon their expression 
of RRM1 compared to the parent cell line: Suit-2R and Suit-2R4 have reduced expression whereas 
Suit-2R2, Suit-2R3 and Panc-R have a high expression. The cell lines can be further divided on  
relationship between RNA and RMM1 protein levels. In the Suit-2G+ cell line the effect is clear 
whereas there is no relationship in the Suit-2R/Panc-R cell lines suggesting that the level is altered 
post-transcriptionally. This also may explain that except for possibly Suit-2R4, the modifications to 
RRM1, whether by siRNA interference or heterologous expression, fail to alter resistance to 
gemcitabine. Though it has been shown in these two experiments that RRM1 expression can be 
changed, all it effectively does is alter the growth rates, which is to be expected. Therefore, there is 
likely to be a delicate balance that determines how the cell manages replicative stress and the cell 
cycle, through regulation of RRM1.  
 
4.2.2.1 Low RRM1 
 
Suit-2R and Suit-2R4 have reduced RRM1 expression and when observing the proportion of dsDNA 
damage, they share a common trait: a significant reduction in DNA damage compared to the parent 
Suit-2 line in the presence of gemcitabine. When treated with gemcitabine, there must be mitigating 
measures to prevent significant replicative DNA damage, this may be in the form of ATM or ATR 
pathways that recruit downstream repair kinases. Whatever the repair mechanisms, we can be 
confident there are fundamental differences between Suit-2R and Suit-2R4 by reviewing the basal 
and radiation controls. In Suit-2R, basal levels and induced levels of DNA damage from gamma 
radiation seem equivalent to the parent cell line, whilst in Suit-2R4 basal levels of dsDNA damage 
seem particularly low but they seem to be more sensitive, not less, to gamma radiation. It can be 
concluded that low RRM1 expression is associated with reduced gemcitabine induced dsDNA 
damage, but this may not be through a general pathway protecting against DNA breaks. It appears 
to be through at least different mechanisms.  
 
Suit-2R and Suit-2R4 exhibit further differences, especially in resistance levels as one is high and one 
is low but also one grows significantly faster. Cell cycle analysis also demonstrate divergent 
attributes. Suit-2R have a large proportion of cells in G1 and do not exhibit an S phase widening in 
the presence of gemcitabine, which would be expected with replicative stress induced by the drug. 
Suit-2R4 has more cells in G2 than G1 phases and also does not have a large S-phase component in 
the presence of gemcitabine, in fact the S-phase component actually decreases in detached Suit-2R4 
cells. Suit-2R contain the fewest cells in G2 of any of the clonal cells observed. Those cells that have 
detached from the plate (mitotic death) have a large S-phase component. Suit-2R4 cells that have 
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detached demonstrate an even distribution at all phases at 50nM of gemcitabine, and at 250nM the 
S-phase, although significant, is not as large as in Suit-2R.  
 
In summary, Suit-2R cells have viable cells in G1 and, in comparison to Suit-2R4, less cells have 
progressed in to G2. The dying Suit-2R cells seems to be mainly in S-phase whilst a greater proportion 
of Suit-2R4 cells are in G1 (having failed to enter S-phase at all) at the point of death.  
 
The checkpoint regulators p21 and Chk1 will be upregulated when a cell enters cell cycle arrest 
between G1/S or G2/M. Arrest contrasts with a cessation of growth, in being an active process. The 
expression of p21 and Chk1 levels in Suit-2R are considerably lower than was seen in the parent cell 
line. Combining this with the fact that Suit-2R is growing slowly, and that this cell line has a reduced 
level of ribonucleotide reductase, it indicates that this could be a modification to avoid cell cycle 
arrest and instead maintain a slow and measured cell division (perhaps pausing rather than arresting 
before entering S phase). It is notable that the majority of Suit-2R cells are in G1, suggesting that Suit-
2R delays the G1/S transition without arresting. Given the low level of RRM1 it is reasonable to 
assume that this is because of limiting levels of nucleotides. The problem for the Suit-2R cells would 
be the high level of assumed replicative stress and a possible compensatory mechanism may be the 
downregulation, post-transcriptionally, of Cyclin D1, most significantly D1a. These cells can therefore 
be predicted to have a very low level of CDK4-driven S-phase entry, reducing replicative stress. 
 
Once again in contrast to Suit-2R, Suit-2R4 shows an elevated level of Chk1, which maybe causing 
checkpoint induction between G2/M as noted on cell cycle analysis. p21 is downregulated suggesting 
that checkpoint control is not as active as seen in the parent strain and it could be hypothesized that 
the low level is matched by an increased passage through the G1/S checkpoint. Given the low level 
of RRM1, this is likely to result in replicative stress but Cyclin D1 is elevated, as opposed to reduced 
as seen in Suit-2R. It can therefore be assumed there is a drive through S-phase with a high level of 
replicative stress and there is no obvious compensation mechanism involving Cyclin D1. Not only are 
the levels of Cyclin D1 high (increase levels of CDK activity), the most stress inducing isoform (D1a) is 
predominantly expressed.  Once it passes S-phase, the cell then pauses or arrests in G2/M.  
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4.2.2.1 High RRM1 
 
Suit-2R2 and Suit-2R3 have high RRM1 expression, suggesting excess levels of ribonucleotide 
reductase compensating for the inhibition by gemcitabine. Hence, they are able to supply nucleotides 
required for DNA replication and avoid this element of replicative stress. This appears to be a post-
transcriptional increase, as the RNA levels are less than the parent in both Suit-2R2 and Suit-2R3. 
Reviewing this in combination with the dsDNA damage, Suit-2R2 has reduced damage at a basal level 
and at 50nM of gemcitabine treatment, as would be expected with increased nucleotides, whereas 
Suit-2R3 has higher basal dsDNA breaks with reduced damage at 50nM gemcitabine. This is indictive 
of more efficient management of gemcitabine induced DNA damage. Both cell lines have increased 
damage at 8Gy radiation implying that there is not an improvement in overall DNA repair to explain 
gemcitabine resistance. Although, the increased supply of nucleotides in the presence of gemcitabine 
may be a pertinent fact in the management of DNA damage. Given that the high IC50 for Suit-2R3 
implies it has the greater ability to manage gemcitabine induced dsDNA breaks, although at very high 
levels of the drug this appears to breakdown. The reduced level of RRM1 in Suit-2R3 at high doses of 
gemcitabine  treatment, may starve this cell line of nucleotides, preventing entry into S phase. While 
for Suit-2R2 these cells enter S phase to suffer DNA damage and replicative stress.  
 
 There is a variation in how these cells respond to gemcitabine exposure, Suit-2R2 increases 
expression of RRM1 and Suit-2R3 reduces it. It is difficult to know at what thresholds each cell has 
regarding how to balance RRM1 production to compensate the cytostatic and cytotoxic effects of 
gemcitabine. In either case, it affects the DNA damage that can be sustained and repaired and will 
reflect how the cell cycle is controlled.  
 
Suit-2R3 depicts a widening of the S-phase as gemcitabine increases and is the only cell to 
demonstrate this outside of the control cell lines. This reflects the replicative stress the cell is under 
due to gemcitabine, despite it being more resistant than the controls. These cells are still progressing 
to G2 and those adherent to the plate have 43% in S phase but almost 21% are in G2. There is a 
marked difference in combining cells in the supernatant because G1 and S phase death is not seen, 
at 250nM of gemcitabine, almost half the cells are in G2. This G2 predominance is not seen as 
significantly in any other cell line. These cells appear willing to undergo replicative stress, and this 
may be a feature even in the absence of gemcitabine, which could explain why at the basal there are 
more dsDNA breaks than in control cells. They are willing to continue through S-phase in the presence 
of double strand breaks. Suit-2R2 cells have the opposite effect, as over half the attached cells are in 
G1 suggesting they are not willing to undergo replicative stress. The cells that included with the 
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supernatant demonstrate widespread death at G1 and S, especially at the higher dose of 
gemcitabine. It can be stated that these two cell lines have differing strategies in overcoming 
replicative stress, just as Suit-2R and Suit-2R4 have different strategies: Suit-2R2 pauses the cell cycle 
to prevent replicative stress and Suit-2R3 accepts it and drives into G2 at the cost of abnormal DNA 
replication possibly leading to inappropriate mitosis.   
 
Suit-2R3 has a high level of ribonucleotide reductase and therefore less supply constraints to the 
nucleotide levels, improving its ability to undergo replication. The most notable checkpoint changes 
are that p21 levels are equivalent to the parent strain and Chk1 levels are upregulated. This cell line 
may maintain an ability for G2/M cell cycle arrest to avoid damage from gemcitabine. Checkpoint 
control in this case seems to protect the cell and as with Suit-2R4, stress induction is increased, but 
instead is compensated for by an increased supply of nucleotides. Suit-2R2 which also has a high level 
of ribonucleotide reductase, has a reduction in p21 suggesting deficiency in checkpoint control. This 
reflects the reduction in the expression of the most stress inducing isoform of Cyclin D1; D1a.  
 
Panc-R is similar to Suit-2R2 and Suit-2R3 with high expression of RRM1, but unlike those cell lines it 
correlates with a higher RNA transcript production. In that respect it is similar to the Suit-2G+ cell line 
which is also has increased RRM1 expression at the RNA level. This cell lines also sustains less dsDNA 
damage, especially at 250nM of gemcitabine treatment compared to the Panc-1 cell line, with similar 
levels at radiation controls. From the perspective of the cell cycle, the viable cells show stability of 
phases with stable S-phase at all doses of gemcitabine. When the supernatant is included, it is clear 
that there is death in all phases of the cell cycle. Therefore, the Panc-R cell line in common with Suit-
2R3 and Suit-2R4, does not pause before S-phase in order to avoid replicative stress and DNA 
damage. In contrast to Suit-2R3 and Suit-2R4, Panc-R may restrict cell cycle transition through 
checkpoints (elevated p21 levels) and reduced drive into S-phase (reduced Cyclin D1, with the less 
stress inducing Cyclin D1b). Panc-1 cells exhibit a homozygous phenotype at the G870A SNP, where 
there is a G allele (Figure 37). This nucleotide position affects the frequency of splicing of CyclinD1 
resulting in more of the D1b variant. This variant appears to be related to tumourigenesis and lower 
replicative stress. The Panc-R cell line further reduces stress by lowering the total level of Cyclin D1 
levels. It is not surprising therefore, that no gemcitabine sensitivity develops from further knockdown 
of the protein.  
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4.3 Summary  
 
In the generation of the aims of this thesis, it was assumed that resistance to gemcitabine could be 
determined genetically in sub-clones of cancer cells, which could then be selected for. Furthermore, 
it was assumed that another way to reach a state of resistance would be for cells to adapt in the 
presence of gemcitabine. It was not clear whether this represented two distinct survival mechanisms 
or whether this was two methods of reaching the same destination. In addressing these aims, a series 
of hypotheses were based on the known action of gemcitabine. The phosphorylation process, the 
cytotoxic and cytostatic effects all require investigation before trying to understand how a pancreatic 
cancer cell survives treatment with gemcitabine. In the presence of gemcitabine, a survival strategy 
would be to increase the level of ribonucleotide reductase activity and/or increase the capacity for 
DNA repair. It is well established that stress of any type can lead to changes in expression that are 
maintained during that period and for a short time afterwards. The observation that RRM1 increased 
dramatically in cells exposed to gemcitabine was therefore not surprising. The question then arises 
could such a cellular state be present in sub-populations prior to gemcitabine exposure and then be 
selected to produce the same resistance effect but with greater stability given the genetic pre-
determination.  Three of the selected clone lines (Suit-2R, Suit-2R3, Panc-R) did have high levels of 
ribonucleotide reductase, at initial review this could suggest convergent evolution with a single 
mechanism of resistance. However, two clonal cell lines had low levels of ribonucleotide reductase, 
making it obvious that the clonal populations are not just reliant on a single mechanism. Further 
analysis elucidated yet more differences and at least four resistance mechanisms can be seen: 
 
A. Significantly increased RRM1 to maintain or increase nucleotide pools in order to overcome 
replicative stress (Suit-2G+) 
 
B. Prevent S-phase entry through: 
 
1. Encouraging a pause at the G1/S transition by starving the cell of nucleotides due to 
low ribonucleotide reductase and reduced level of Cyclin D1 (Suit-2R) 
 
2. Either through low levels of Cyclin D1 or cell cycle arrest perhaps via Chk1 whilst 
ameliorating replicative stress with an elevated level of RRM1 providing nucleotides 
for completion of S-phase once entered (Suit-2R2) 
 
C. Drive through S-phase accepting replicative stress and arrest or pause at the G2/M checkpoint 
in order to mitigate failing mitosis. With or without high RRM1 to overcome replicative stress 
(Suit-2R3, Suit-2R4) 
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D. Similar to A with developing a measured and controlled transition through the phases with 
high levels of ribonucleotide reductase to compensate for replicative stress, but in this case  
based on genetic or epigenetic programming (Panc-R) 
 
These resistance mechanisms in the clonal populations is not surprising given the significant 
heterogeneity in many types of malignancies, and so it is to be expected that there will be no singular 
process to ensure survival, even within a single immortalised cell line. A cell’s ability to maintain DNA 
replication and mitosis is fundamental to survival, whether it is through high volume division or 
measured slow growth. These strategies lead to dramatically different degrees of resistance as well 
as growth rates. The ability to regulate cell cycle progression is dependent on a complex interwoven 
network of many different proteins, and a cancer cell already has aberrant functionality to survive 
under conditions the parent cell would not tolerant. Suit-2 and Panc-1 cell lines are able to survive 
whether gemcitabine is given as part of culture medium or as a pulsed regimen, and undergo further 
adaptations once the drug has been removed. There is a versatility that cannot be underestimated 
because pancreatic cancer cells are able to endure a significant amount of cytotoxicity and still be 
able to control their cell cycle, as has been shown. The only strategy to cause widespread cell death 
is to treat with high doses of gemcitabine at a higher frequency which is likely to kill all other cells, 
ultimately detrimental to a patient.  
 
4.4 Clinical applicability  
 
The chemotherapy treatment of a patient with pancreatic cancer is a staggered approach. Given 
there is toxicity to all cells and not just the tumour, high doses at frequent intervals are simply 
unfeasible. The paced approach allows recovery for all cells and potentially the tumour and, if a solid 
mass is exposed to gemcitabine, there will certainly be a degree of cell death. There are clinical 
considerations to how drugs are administered and the ability to deliver medication as directly as 
possible to the tumour itself. Pancreatic cancer has a particular high fibrotic component, potentially 
restricting access of the drug to the cancer cells. It is unlikely, though not impossible, to cause death 
to all tumour cells without collateral damage. Repeated exposure to chemotherapy will potentially 
eliminate more and more cancer cells, and the cells that remain have an opportunity to either adapt 
to survive the next wave of toxicity. They are selected for because of an innate ability to repair DNA 
damage and regulate their cell cycle. It is tempting to state that the clonal isolation resistance 
technique is more realistic to modern chemotherapy regimens, but a solid tumour is not equivalent 
to a monolayer of cancer cells on a plate. If a patient has a surgical excision of cancerous lesion, then 
chemotherapy may be acting upon single cells or small clusters of remnant cells in the local 
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environment or seeded elsewhere. Selection of resistance in a solid tumour, as with the adaptive 
technique, would allow survival of cancer cells that in themselves are not resistant, but which are 
protected by surrounding cells, in the case of a tumour both cancer and normal cells. Thus both 
methods of developing resistant pancreatic cancer cell lines have clinical relevance and neither is an 
ideal representation.   
 
If a second chemotherapy agent was added to the treatment of pancreatic cancer, then a cell would 
have to withstand two potentially cytotoxic processes, providing the medications had different 
mechanisms of action. This double insult would make it significantly harder to survive, which applies 
equally to normal cells. The considerations above regarding cell exposure and survival would have to 
be applied to two separate mechanisms of action. The chemotherapy regime would require 
appropriate dosing and timing to account for complications of the additional chemotherapy agent. 
This was certainly the outcome of the ESPAC-4 trial which found that an additional 2.5 months of 
survival was achieved with the addition of capecitabine to gemcitabine chemotherapy. Consequently 
608 adverse outcomes were reported in the dual drug cohort compared to 481 in the gemcitabine 
group (5). There is a trend for multiple chemotherapy regimens in the treatment of many cancers, as 
demonstrated by the current trials of FOLFIRINOX in pancreatic cancer (27, 32). As mentioned above, 
a broad-based strategy to chemotherapy is a blunt tool and a more precise tailored approach would 
be beneficial for the patient and overall survival.   
 
4.5  A personalised approach 
 
From the experiments above, it would be reasonable to select RRM1 and Cyclin D1 as markers of 
gemcitabine resistance. In an ideal world an increase or decrease in one of these markers could 
theoretically determine what type of gemcitabine resistance, if any, the cells had acquired. That way 
unnecessary adverse effects and time wasted could easily be avoided if we had an effective way of 
dealing with different forms of resistance.  
 
A group from Japan performed similar resistance development experiments in BxPC-3 cells and found 
high RRM1 expression should be targeted by non-gemcitabine therapies (58). Our own group 
reviewed tumour tissue of 303 patients from the ESPAC trials and found that intratumoural RRM1 
expression is not related to survival (85). And yet there have been retrospective studies of trials and 
a meta-analysis of large numbers of pancreatic patients who received gemcitabine, reporting that 
high RRM1 expression leads to poorer survival (46, 86, 87). There has been significantly less work 
carried out on Cyclin D1. A study of 425 pancreatic ductal cancer patients discovering a variation in 
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survival in patients who have heterozygous/homozygous forms of the Cyclin D1 G870A 
polymorphism. The minor allele was found to be associated with poorer survival (72). Which on the 
basis of this thesis could be explained by Cyclin D1b related resistance.  
 
There are many aspects that need to be considered when interpreting all of this clinical data, 
including retrospective design, geographical variations, baseline cohort standardisation, 
experimental quality assurance, and protein thresholds employed. The conclusions derived from cell 
lines in this thesis have suggested that expression of RRM1 can be used to identify multiple individual 
forms of resistance, some with high and some with low levels of the protein. Assuming a similar 
variety exists in patients, studies of populations would result in confusion. High RRM1 indicating 
resistance in one individual and low RRM1 indicating resistance in another, thus poor survival 
associated with high or low RRM1 expression. Consequently, RRM1 expression in a population will 
be deemed to be not associated at all with survival. This possibility would explain the contradictions 
seen in the literature.  
 
The role of hENT1 has been extensively studied in our unit, leading to publications that have 
suggested that pancreatic cancer patients with low expression of the transporter should not receive 
adjuvant gemcitabine chemotherapy. Multiple publications, in the form of retrospective studies and 
systematic reviews, have stated that increased hENT1 predicts a higher survival in patients with 
pancreatic cancer (42, 46, 88, 89). Note there have been no validated prospective studies reviewing 
hENT1 expression. It is logical to assume that gemcitabine delivery may impact the resistance 
process, such that cell lines will have low dsDNA damage, especially when there is low RRM1 
expression. It would be a reasonable argument that intracellular gemcitabine concentration and 
supply of nucleotide pools would affect the effectiveness of gemcitabine. Thus, it could be 
hypothesized that by combining RRM1 and hENT1 expression, we  may be able to predict patients 
that would benefit from this chemotherapy agent. Figure 48 depicts unpublished survival data from 
ESPAC3 patients that underwent adjuvant chemotherapy with gemcitabine, stratified by intra-
tumoural expression of hENT1 and RRM1.  This data is included within this thesis with the permission 
of the pancreas research group  at the University of Liverpool.
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a) Overall survival according to RRM1 expression
b)     Survival with high hENT1, stratified by RRM1 expression c) Survival with low hENT1, stratified by RRM1 expression 
 
d)     Survival with high RRM1, stratified to hENT1 expression       e) Survival with low RRM1, stratified to hENT1 expression 
 
Figure 48 Kaplan Meier curves to demonstrate overall survival in ESPAC-3 (ver 2) pancreatic cancer patients 
treated with adjuvant gemcitabine. a) Overall survival correlating to RRM1 level, b) & c) High/Low hENT1 
expression stratified by RRM1 expression, d) & e) High/Low RRM1 expression stratified by hENT1 expression. 
Figure (a) depicts no difference between RRM1 alone but in tumours with high hENT1 where there are higher 
levels of gemcitabine, there is not only generally increased survival (b,c) but a poorer prognosis if RRM1 is high 
(c). This suggests tumours are able to undergo DNA replication given that there is less gemcitabine causing 
toxicity, driving the cell cycle forward. This is also shown in figure d where low hENT1 and high RRM1 causes a 
stark reduction in overall survival. This effect is not seen with low RRM1 at any level of hENT1 (b,e)
High RRM1
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Even though RRM1 alone shows no change to overall survival when it is correlated with hENT1 
expression, there are still prominent changes that deserve exploration. If gemcitabine delivery to a 
cell is reduced through low hENT1 expression then malignant potential remains, and if the nucleotide 
pool is maintained through high RRM1 expression then the cell is able to replicate with potential DNA 
damage. The damage is minimised because the gemcitabine level is low. Patients whose cancer 
exhibits low RRM1, at whatever level of hENT1, potentially have cancer cells that are unable to enter 
S-phase, because of starvation of nucleotides. Thus, resistance cells can survive until gemcitabine is 
degraded. Figure 48e depicts increased survival in patients with high hENT1 in cells with low RRM1, 
as the high level of intracellular gemcitabine will overwhelm the ribonucleotide reductase, though 
this effect is not statistically significant.  
 
There is certainly a potential to stratify the administration of gemcitabine monotherapy according to 
intra-tumoural levels of hENT1 and RRM1. On the basis of this thesis, this could be taken further by 
reviewing the allele type of the G870A polymorphism (indicating the relative levels of D1a and D1b), 
and the absolute level of Cyclin D1.  This may not only select patients that would benefit most from 
gemcitabine but also those who would require an additional chemotherapy agent. The only way to 
pursue this hypothesis would be a blinded randomised control trial with biomarker stratification.  
 
4.6 Future considerations 
 
A couple of studies have specifically observed changes in RRM1 with adjunctive chemotherapy agents 
in conjunction with gemcitabine. Deferasirox is an oral iron chelator and significantly reduces the 
expression of RRM1 and RRM2 when given with gemcitabine in mouse models. It was found that 
increased apoptotic indices were achieved, suggesting increased therapeutic potential of the 
chemotherapy combination, though an exact synergistic mechanism was not been established (90). 
The selective MEK1/2 inhibitor, Pimasertib functions by halting the commonly aberrant RAS/RAF 
pathway from the mutant KRAS gene, found in pancreatic cancer. Its antiproliferative activity stems 
from halting the phosphorylation process and activation of ERK, which activates downstream targets 
of cell cycle regulators, of which one interestingly is Cyclin D. The group discovered a reduction in 
RRM1 in vitro and in vivo and discovered slower tumour growth when Pimasertib was combined with 
gemcitabine. This synergistic mechanism certainly is in accordance the principles of cell cycle 
dysregulation, affording an increase in the cytotoxic and cytostatic effects of gemcitabine (91). A Chk1 
inhibitor has been used in conjunction with gemcitabine, on the basis that abrogation of the S and 
G2/M checkpoints would contribute to the cytotoxicity of gemcitabine. They found using in vitro 
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pancreatic cancer cells that there was reduced expression of RRM1 which sensitised the cells to 
gemcitabine (76). The use of Chk1 inhibition has been theorised as a target in pancreatic cancer 
frequently and this thesis has shown some resistant cell lines that express high levels of Chk1 protein 
(77, 78). This may be a checkpoint marker that could be inhibited for synergistic and cumulative 
tumour toxicity with gemcitabine.  
 
There are many studies in pancreatic cancer that have discovered multiple cellular adaptations in 
order to sustain malignant potential. This thesis has demonstrated a multifaceted approach to 
gemcitabine resistance dependent on the cells ability to repair DNA and regulate its cell cycle. There 
are many checkpoint markers and cell phase transition recruiters whose expression, in either 
direction, may increase malignant potential. It is difficult to pinpoint specific proteins that may affect 
widescale change, especially in cells that are adapting to chemotherapy. A second agent may be the 
answer to target resistance, as is the current trend of multiple agent regimens. But a balance has to 
be achieved with patient toleration and degree of tumour specificity. The biomarkers discussed in 
this thesis will allow further stratification in trials of gemcitabine based therapy combinations.
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